US20210244695A1 - Methods and Compositions for Supporting Renal Health - Google Patents
Methods and Compositions for Supporting Renal Health Download PDFInfo
- Publication number
- US20210244695A1 US20210244695A1 US17/240,605 US202117240605A US2021244695A1 US 20210244695 A1 US20210244695 A1 US 20210244695A1 US 202117240605 A US202117240605 A US 202117240605A US 2021244695 A1 US2021244695 A1 US 2021244695A1
- Authority
- US
- United States
- Prior art keywords
- bhb
- ketonic
- composition
- citrate
- renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 289
- 238000000034 method Methods 0.000 title claims abstract description 94
- 230000036541 health Effects 0.000 title claims abstract description 60
- 230000008093 supporting effect Effects 0.000 title claims abstract description 34
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 77
- 239000013078 crystal Substances 0.000 claims abstract description 75
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims abstract description 68
- 238000011282 treatment Methods 0.000 claims abstract description 68
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims abstract description 62
- 238000001556 precipitation Methods 0.000 claims abstract description 49
- 239000003112 inhibitor Substances 0.000 claims abstract description 43
- 208000026292 Cystic Kidney disease Diseases 0.000 claims abstract description 32
- 239000000556 agonist Substances 0.000 claims abstract description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 95
- 210000003734 kidney Anatomy 0.000 claims description 51
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 43
- 206010038423 Renal cyst Diseases 0.000 claims description 26
- 239000002243 precursor Substances 0.000 claims description 23
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 20
- 206010063837 Reperfusion injury Diseases 0.000 claims description 18
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 17
- 208000033626 Renal failure acute Diseases 0.000 claims description 17
- 201000011040 acute kidney failure Diseases 0.000 claims description 17
- 230000000302 ischemic effect Effects 0.000 claims description 17
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 claims description 3
- 201000008645 Joubert syndrome Diseases 0.000 claims description 3
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims description 3
- 201000008643 Meckel syndrome Diseases 0.000 claims description 3
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 3
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 3
- 229960003459 allopurinol Drugs 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims description 3
- 229960005101 febuxostat Drugs 0.000 claims description 3
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003838 lesinurad Drugs 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 201000002648 nephronophthisis Diseases 0.000 claims description 3
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000424 rasburicase Drugs 0.000 claims description 3
- 108010084837 rasburicase Proteins 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 208000022330 Acquired cystic kidney disease Diseases 0.000 claims description 2
- 208000036075 Autosomal dominant tubulointerstitial kidney disease Diseases 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 208000024940 Dent disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 claims description 2
- 241001263478 Norovirus Species 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 208000026233 benign cystic nephroma Diseases 0.000 claims description 2
- 208000014747 cystic renal cell carcinoma Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000009242 medullary sponge kidney Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 abstract description 95
- 239000003795 chemical substances by application Substances 0.000 abstract description 76
- 230000001225 therapeutic effect Effects 0.000 abstract description 69
- 208000007976 Ketosis Diseases 0.000 abstract description 43
- 230000004140 ketosis Effects 0.000 abstract description 43
- 208000031214 ciliopathy Diseases 0.000 abstract description 17
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 230
- 208000031513 cyst Diseases 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 45
- 241000700159 Rattus Species 0.000 description 40
- 230000000694 effects Effects 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 31
- 150000002576 ketones Chemical class 0.000 description 31
- 206010011732 Cyst Diseases 0.000 description 28
- 230000000512 lipotoxic effect Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 235000005911 diet Nutrition 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- 230000037396 body weight Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 19
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 19
- 230000009467 reduction Effects 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000000926 neurological effect Effects 0.000 description 17
- 238000012384 transportation and delivery Methods 0.000 description 17
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- -1 hydroxylbutyl Chemical group 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 235000001968 nicotinic acid Nutrition 0.000 description 13
- 239000011664 nicotinic acid Substances 0.000 description 13
- 229960003512 nicotinic acid Drugs 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000012190 activator Substances 0.000 description 12
- 239000013066 combination product Substances 0.000 description 12
- 229940127555 combination product Drugs 0.000 description 12
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 230000037406 food intake Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000003907 kidney function Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 108700043492 SprD Proteins 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 230000001575 pathological effect Effects 0.000 description 11
- 235000020924 acute fasting Nutrition 0.000 description 10
- 150000001860 citric acid derivatives Chemical class 0.000 description 10
- 230000000378 dietary effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 239000013589 supplement Substances 0.000 description 10
- 206010061818 Disease progression Diseases 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 235000019437 butane-1,3-diol Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000005750 disease progression Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000003278 mimic effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 8
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 235000020887 ketogenic diet Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000020828 fasting Nutrition 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000004081 cilia Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000000651 myofibroblast Anatomy 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 208000037273 Pathologic Processes Diseases 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000000366 juvenile effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000009054 pathological process Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 210000002726 cyst fluid Anatomy 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 235000020805 dietary restrictions Nutrition 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- ARJKMWXLIHZLQZ-UHFFFAOYSA-N sch 900271 Chemical compound C=1C(=O)OC=2NC(=O)NC(=O)C=2C=1CCCC1(C)CC1 ARJKMWXLIHZLQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 4
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical class C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 3
- CUTZNERBKDMLAP-QWWZWVQMSA-N 1268882-43-4 Chemical compound C([C@H]1C[C@H]11)C2=C1NN=C2C(=O)O CUTZNERBKDMLAP-QWWZWVQMSA-N 0.000 description 3
- CGAMDQCXAAOFSR-UHFFFAOYSA-N 8-chloro-3-pentyl-7h-purine-2,6-dione Chemical group O=C1NC(=O)N(CCCCC)C2=C1NC(Cl)=N2 CGAMDQCXAAOFSR-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000007309 Fischer-Speier esterification reaction Methods 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 3
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 3
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102100037469 Protein DEPP1 Human genes 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000020934 caloric restriction Nutrition 0.000 description 3
- 238000007675 cardiac surgery Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019138 food restriction Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- QMEIHTAHWHSQCK-UHFFFAOYSA-N n-propanoyl-n-(1h-pyrazol-5-yl)cyclohexene-1-carboxamide Chemical compound C1=CNN=C1N(C(=O)CC)C(=O)C1=CCCCC1 QMEIHTAHWHSQCK-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000001508 potassium citrate Substances 0.000 description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- LRDUPNFEHGGCHQ-UHFFFAOYSA-N 2-(2-hydroperoxy-2-oxoethyl)-2-hydroxybutanedioic acid Chemical compound OOC(=O)CC(O)(C(O)=O)CC(O)=O LRDUPNFEHGGCHQ-UHFFFAOYSA-N 0.000 description 2
- MDOKNTXSIGQKCJ-UHFFFAOYSA-N 3-(3-oxobutanoyloxy)butyl 3-oxobutanoate Chemical group CC(=O)CC(=O)OC(C)CCOC(=O)CC(C)=O MDOKNTXSIGQKCJ-UHFFFAOYSA-N 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- ZJTXSGLJNBAMJS-UHFFFAOYSA-N 5-butyl-1h-pyrazole-3-carboxylic acid Chemical compound CCCCC1=CC(C(O)=O)=NN1 ZJTXSGLJNBAMJS-UHFFFAOYSA-N 0.000 description 2
- DJDHHXDFKSLEQY-UHFFFAOYSA-N 5-methylpyridine-3-carboxylic acid Chemical compound CC1=CN=CC(C(O)=O)=C1 DJDHHXDFKSLEQY-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 230000035495 ADMET Effects 0.000 description 2
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 2
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 description 2
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 101150103290 Hcar2 gene Proteins 0.000 description 2
- 101000821902 Homo sapiens Solute carrier family 22 member 11 Proteins 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000000614 Marden-Walker syndrome Diseases 0.000 description 2
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100021493 Solute carrier family 22 member 11 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 2
- 229950000146 acifran Drugs 0.000 description 2
- 229960003526 acipimox Drugs 0.000 description 2
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000037416 cystogenesis Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- CUTZNERBKDMLAP-UHFFFAOYSA-N gtpl5785 Chemical compound C1C2=C(C(=O)O)NN=C2C2CC21 CUTZNERBKDMLAP-UHFFFAOYSA-N 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 229950007593 homonicotinic acid Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000002361 ketogenic effect Effects 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000002370 magnesium bicarbonate Substances 0.000 description 2
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 2
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 description 2
- 229940005650 monomethyl fumarate Drugs 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000006636 nicotinic acid Chemical class 0.000 description 2
- 235000021232 nutrient availability Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- SDQCJRRWHYIOAP-UHFFFAOYSA-N pyrazine-2-carboxylic acid pyridazine-4-carboxylic acid Chemical compound N1=C(C=NC=C1)C(=O)O.N1=NC=C(C=C1)C(=O)O SDQCJRRWHYIOAP-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
- PUPZLCDOIYMWBV-BYPYZUCNSA-N (S)-butane-1,3-diol Chemical compound C[C@H](O)CCO PUPZLCDOIYMWBV-BYPYZUCNSA-N 0.000 description 1
- UKVPNJSNIKHGOJ-UHFFFAOYSA-N 2-(3-hydroxybutanoyloxy)butanoic acid Chemical group CCC(C(O)=O)OC(=O)CC(C)O UKVPNJSNIKHGOJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 235000020926 24-h fasting Nutrition 0.000 description 1
- AOWPVIWVMWUSBD-UHFFFAOYSA-N 3-hydroxybutyl 3-hydroxybutanoate Chemical compound CC(O)CCOC(=O)CC(C)O AOWPVIWVMWUSBD-UHFFFAOYSA-N 0.000 description 1
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical group CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150001792 ANKS6 gene Proteins 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical group CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N CC(=O)CC(C)C Chemical compound CC(=O)CC(C)C NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- MZKOPZKKOGOTLC-UHFFFAOYSA-N CC(=O)CC(C)OC(=O)CC(O)(CC(=O)OC(C)CC(=O)O)C(=O)OC(C)CC(=O)O Chemical compound CC(=O)CC(C)OC(=O)CC(O)(CC(=O)OC(C)CC(=O)O)C(=O)OC(C)CC(=O)O MZKOPZKKOGOTLC-UHFFFAOYSA-N 0.000 description 1
- RPXLBTVALJGOTA-UHFFFAOYSA-N CC(C)CCOC(=O)CC(O)(CC(=O)OCCC(C)O)C(=O)OCCC(C)O Chemical compound CC(C)CCOC(=O)CC(O)(CC(=O)OCCC(C)O)C(=O)OCCC(C)O RPXLBTVALJGOTA-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N CCCC(C)O Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- YTKRCILVVLXFCL-UHFFFAOYSA-N CCCC(C)OC(=O)CC(O)(CC(=O)OC(C)CCO)C(=O)OC(C)CCO Chemical compound CCCC(C)OC(=O)CC(O)(CC(=O)OC(C)CCO)C(=O)OC(C)CCO YTKRCILVVLXFCL-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 1
- 208000025678 Ciliary Motility disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010411 Congenital central nervous system anomaly Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 201000002650 Ellis-van Creveld syndrome Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010067265 Heterotaxia Diseases 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108091006343 Hydroxycarboxylic acid receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000010043 Jeune syndrome Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-M O=C([O-])CC(O)(CC(=O)O)C(=O)O.[Na+] Chemical compound O=C([O-])CC(O)(CC(=O)O)C(=O)O.[Na+] KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001397 Poly-beta-hydroxybutyrate Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 201000006760 Senior-Loken syndrome Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 208000031733 Situs inversus totalis Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 0 [1*]OC(=O)CC(O)(CC(=O)O[3*])C(=O)O[2*] Chemical compound [1*]OC(=O)CC(O)(CC(=O)O[3*])C(=O)O[2*] 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical group CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013216 cat model Methods 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000020829 intermittent fasting Nutrition 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000741 isoleucyl group Chemical class [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-AVQMFFATSA-N linoelaidic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-AVQMFFATSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- ZMKDEQUXYDZSNN-UHFFFAOYSA-N linolelaidic acid Natural products CCCCCCCCC=CCC=CCCCCC(O)=O ZMKDEQUXYDZSNN-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002751 molybdenum Chemical class 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 231100000637 nephrotoxin Toxicity 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 201000003455 orofaciodigital syndrome I Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 description 1
- 208000028589 polycystic liver disease Diseases 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 208000008797 situs inversus Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 description 1
- 229960001256 tolvaptan Drugs 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Definitions
- Renal disease is a major health issue. Among the various renal conditions that afflict people, renal cysts are present in numerous pathologies of the kidney. Polycystic kidney disease (PKD) is an especially serious condition with high morbidity and mortality. Autosomal dominant polycystic kidney disease (ADPKD) is considered the most common life-threatening monogenic disease.
- the PKD disease state is characterized by the growth of fluid-filled cysts in the kidneys which progressively enlarge, leading to destruction of normal renal tissue and function. Renal cyst growth in PKD is driven by several growth factors, hormones and cytokines that are present in the cyst fluid and which stimulate the cyst-lining epithelial cells.
- Polycystic kidney disease is one of several pathological conditions classified as a ciliopathy.
- Cilia are microtubule-containing structures that protrude from the surface of most cells types.
- Cilia especially immotile primary cilia, act as a “cellular antenna” with various functions including sensory and cell-to-cell communication roles.
- Many pathological conditions are associated with mutations that result in abnormal cilial formation or function.
- Ketosis is characterized by elevated abundance of ketone bodies in blood and other compartments. Ketosis is a metabolic pathway induced by low glucose conditions, for example, being induced by low-carbohydrate diet or fasting. Numerous health benefits appear to be associated with dietary ketosis, including weight loss and appetite control, improved cholesterol status, and stabilization of blood glucose and insulin. The use of ketogenic diets has been applied to control epilepsy in children and blood glucose in Type 2 diabetics.
- ketogenic diets may be of benefit in addressing many other conditions, for example, in the context of kidney injury in surgical subjects, caloric restriction was found to have protective effect on renal function, as described in Grundmann et al., Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial. J Am Heart Assoc 7, (2018.)
- the mechanisms by which ketosis acts on pathological processes and conditions is not well understood, and previously recognized dietary benefits have not been translated to practical applications and interventions. Accordingly, there is a need in the art for an improved understanding of the molecular signaling mechanisms or other physiological effects by which ketosis achieves health benefits.
- long-term adherence to ketogenic diets is difficult and compliance is poor for many, if not most, subjects. Accordingly, there is further need in the art for novel therapies that harness the beneficial effects of ketosis while being readily administered or applied.
- BHB beta hydroxybutyrate
- compositions for promoting health, preventing disease, and treating pathological conditions.
- These compositions termed “ketonic compositions” herein, comprise BHB, BHB precursors that convert to BHB in vivo, BHB-like molecules, and functional mimics of BHB, including chemically unrelated species, that recapitulate the beneficial signaling activities of BHB.
- the ketonic compositions can be formulated as dietary supplements, for convenient oral administration.
- the ketonic compositions comprise inexpensive off-the-shelf ingredients with long-established safety profiles, and thus can be provided without the need for clinical trials, and may be utilized without the need for a prescription.
- the scope of the invention encompasses novel uses of GPR109A agonists. Many such agents have been previously developed and clinically investigated for other purposes, and may be repurposed in the methods of the invention for novel therapeutic applications.
- the scope of the invention encompasses novel compositions and methods for improving renal health, and preventing and treating various conditions of the kidney.
- the inventions disclosed herein are advantageously applied for subjects at risk of or suffering from various renal cystic conditions, especially polycystic kidney disease.
- the scope of the invention encompasses dietary supplements and uses thereof for promoting renal health by preventing the formation of cysts and selectively destroying cyst epithelial cells.
- ketonic agents may be used to prevent or ameliorate the severity of acute kidney injury, for example, being used as preventative agents prior to surgery to reduce the risk or severity of acute kidney injury associated with surgery.
- ketonic agents may be used to ameliorate the risk or severity of ischemic perfusion injury, for example, as preventative, e.g., presurgical treatments.
- the ketonic agents of the invention may be combined with crystal precipitation inhibitors with synergistic beneficial activity.
- crystal precipitation inhibitors with synergistic beneficial activity.
- citrate a safe and readily available ingredient, is a crystal precipitation inhibitor that can be combined with ketonic agents, for example, in dietary supplements.
- compositions of matter comprising bi-functional molecules made up of a ketonic agent and a crystal precipitation inhibitor, for example, a BHB-citrate combined molecule.
- cystic epithelial cells are metabolically inflexible, being dependent upon glucose and being unable to metabolize fatty acids. Accordingly, in one aspect, the scope of the invention encompasses novel combination products made up of ketonic agents in combination with compositions that are lipotoxic to pathological cells such as polycystic kidney cyst epithelial cells and other undesirable cell types. The co-administration of ketonic agents and lipotoxic compositions provides enhanced preventatives and treatments for PKD cysts and other conditions.
- the scope of the invention encompasses novel means of preventing and treating ciliopathies.
- the ketonic compositions of the invention including exogenous ketones and GPR109A agonists, may be utilized in dietary supplements and therapeutic compositions for ameliorating the risk, onset, and severity of numerous ciliopathies such as PKD and retinitis pigmentosa.
- FIG. 1 is a diagrammatic representation of the effects of a ketogenic diet or the application of ketonic compositions on polycystic kidneys. Without intervention, kidneys are ridden with cysts and cysts expand (left). With sufficient intervention, cysts are reduced and kidneys return towards normal condition (right).
- FIGS. 2A, 2B, and 2C depict the effects of time-restricted feeding in a PKD rat model.
- FIG. 2A depicts the cystic index (percent cystic area) for kidneys of rats on the TRF or AL diet.
- FIG. 2B depicts the total number of cysts per kidney section in AL and TRF animals.
- FIG. 2C depicts cyst sizes of the cysts counted in 2 B.
- FIG. 3 depicts the abundance of pS6-positive cells in cyst-lining epithelia as a percent of the total number of DAPI-stained nuclei PKD rats on AL diet TRF diet.
- FIGS. 4A, 4B, 4C, 4D, and 4E depict the effects of a ketogenic diet on disease progression in juvenile Han:SPRD rats.
- FIG. 4A depicts the cystic index (percent cystic area) from NC (normal chow) and KD (keto diet) cystic rats. [Dr6]
- FIG. 4B depicts serum creatinine.
- FIG. 4C depicts total number of cysts per kidney section.
- FIG. 4D depicts the size of cysts counted in FIG. 4C .
- FIG. 4E depicts quantification of pS6-positive cells in cyst-lining epithelia as a percent of the total number of DAPI-stained nuclei in cysts. Error bars represent SD.
- FIGS. 5A, 5B, and 5C depict PKD progression in rats treated with keto diet.
- FIG. 5A depicts Cystic index (percent cystic area).
- FIG. 5B depicts the total number of cysts per kidney section.
- FIG. 5C depicts the size of cysts counted in FIG. 5B .
- FIGS. 6A, 6B, and 6C depict effects of fasting (acute 48-h fast) in Han:SPRD and WT rats.
- FIG. 6A depicts blood BHB levels in male rats.
- FIG. 6B depicts blood BHB levels in female rats.
- FIG. 6C depicts cystic index (percent cystic area) in kidneys of fasted PKD rats.
- FIG. 7 depicts the cystic index (percent cystic area) in Han:SPRD PKD rats administered BHB, vs. control rats given water or water with salt equivalent to the BHB treatment.
- FIGS. 8A and 8B depict the effects of varying concentrations of BHB and citrate, as well as BHB-citrate combination treatments, in PKD rats.
- FIG. 8A depicts 2-kidney to total body weight ratio in wild type (WT) and Cy+ PKD rats.
- FIG. 8B depicts cystic area (percent cystic area) in kidneys of the treated PKD rats.
- FIG. 9 depicts PKD progression (as assessed by 2-kidney to total body weight ratio) in niacin-treated PKD mice that express GPR109A (Genotype 1), and in GPR109A knockout PKD mice (Genotype 2).
- the various inventions disclosed herein are directed to dietary supplements, pharmaceutical compositions, and other compositions comprising BHB or BHB-related compounds, and the novel uses of such compositions in maintaining health, preventing disease and treating various conditions.
- the support of kidney health and the treatment of kidney disease is encompassed by the compositions and methods of the invention, for example, the treatment of polycystic kidney disease.
- the scope of the invention encompasses compositions which may be used to promote wellness, prevent disease, or treat various conditions.
- the compositions of the invention encompass BHB and other ketone bodies and variants thereof as well as unrelated chemical structures which functionally recapitulate the biological and therapeutic effects of BHB. Therefore, the compositions of the invention will be referred to herein broadly as “ketonic compositions.”
- the ketonic compositions of the invention may comprise any number of ketone bodies, ketone body precursors, ketone body functional mimics, and multifunctional combination products comprising two or more ketone bodies or analogs.
- the scope of the invention encompasses multifunctional combination products comprising ketone bodies or analogs with additional functional agents that augment or synergize the benefits of the ketones.
- the ketonic compositions of the invention comprise novel compositions of matter.
- the ketonic compositions of the invention comprise known compositions of matter that are repurposed for novel uses.
- the ketonic composition of the invention encompasses a ketosis mimic.
- a ketosis mimic is a composition of matter which, when administered to a subject, induces or recapitulates, in whole or in part, processes or states active in ketosis, for example, dietary ketosis, i.e. ketosis induced by fasting or otherwise restricting glucose, for example, a blood ketone level of 0.5mM or greater.
- the ketosis mimic may comprise an exogenous ketone.
- An exogenous ketone is an exogenously applied ketone body that is structurally or functionally like BHB or other ketone bodies found circulating in subjects experiencing ketosis, e.g. dietary ketosis, or which is converted to a ketone body in vivo.
- the ketosis mimic is BHB or a BHB analog.
- BHB beta-hydroxybutyric acid
- STRUCTURE 1 is a ketone that is synthesized in the liver from acetyl-CoA formed from the breakdown of fatty acids via several intermediates and reaction steps. BHB is formed in ketosis or other low glucose conditions.
- BHB may be employed either as the free acid or as a salt or a mixture of both.
- BHB or BHB salts are preferentially administered in oral formulations for gastrointestinal absorption leading to distribution via the circulation and effects of BHB in the body including the kidneys.
- BHB analogs may also be employed in the compositions and methods of the invention.
- Direct administration BHB in its free acid form may be problematic due to its acidity.
- administration of BHB salts may be problematic due to increased salt intake which may be undesired.
- a composition that is converted to BHB in vivo or which mimics BHB may be used in place of free BHB or BHB salts.
- BHB analogs broadly encompasses compositions that (1) are converted to BHB in vivo or (2) have structural similarly to BHB and promote like physiological responses as those promoted by BHB.
- the BHB analog is a precursor of BHB.
- a BHB precursor is a composition that is converted to BHB in vivo via one or more reactions or intermediates.
- the BHB precursor is butyrate.
- the BHB precursor is beta-hydroxy beta-methylbutyrate.
- the BHB precursor is a ketogenic amino acid or a deaminated keto-analogue of a ketogenic amino acid.
- the BHB precursor is acetoacetate (the physiological form of acetoacetic acid).
- the BHB precursor is poly-beta-hydroxybutyrate.
- the BHB precursor is beta-hydroxybutyryloxy-butyrate.
- the BHB precursor is 1,3 butanediol, Structure 2:
- 1,3 butanediol is water soluble and well tolerated by animals, including humans. In the body, it is efficiently converted to BHB by enzymatic and/or chemical action, for example, wherein alcohol dehydrogenase catalyzes metabolism of 1,3-butanediol to beta-hydroxybutyraldehyde, which is subsequently oxidized to beta-hydroxybutyrate by aldehyde dehydrogenase.
- 1,3 butane diol is neutral and can be administered directly without the need to formulate as a salt.
- the BHB precursor is 1,3-butanediol diacetoacetate.
- 1,3-butanediol diacetoacetate is water soluble, well tolerated in animals and converted to BHB in vivo.
- the BHB analog comprises a BHB precursor comprising a fat molecule which is readily converted to ketones in the body.
- the BHB precursor is a medium chain triglyceride (MCT), for example, a triglyceride comprising six to 12 carbon chains.
- MCTs are more efficiently converted to ketones in vivo than shorter or longer chain fats.
- Exemplary MCTs include caproic acid (C6), caprylic acid (C8), capric acid (C10), and lauric acid (C12).
- BHB Esters The BHB analogs of the invention further encompass esters of BHB, and esters of BHB analogs, wherein the oxygen of the hydroxyl group of the BHB carboxylic acid moiety (carbon 1) is conjugated with a hydroxyl group of another compound.
- esters include methyl, ethyl, propyl (e.g. n-propyl or 2-propyl), butyl (e.g. tert-butyl), pentyl, hydroxylbutyl, hydroxylpropyl, glycerol, citrate, or glycol groups joined to the 1 carbon of BHB.
- Other exemplary esters are 3-hydroxybutyrate-(R)-1,3-butanediol monoester.
- Esters of BHB at the 1 carbon eliminate the carboxylic acid group and associated charge. In vivo, these compositions are de-esterified by esterase enzymes, releasing BHB (or the BHB analog or mimic in some cases). Such compositions may have improved solubility, increased membrane permeability, improved stability, more sustained release, and increased tolerance compared to native BHB or BHB analogs.
- Reference to “BHB” and “BHB analogs” herein will be understood to encompass esters of BHB and esters of BHB precursors and mimic compositions. Esters of the 3 carbon are also within the scope of the invention.
- BHB esters are known in the art. Additional BHB esters may include compositions of the formula: STRUCTURE 3
- R1 and/or R2 may be an alkyl moiety, for example, comprising one to twelve carbons, for example, methyl, ethyl, propyl (e.g. n-propyl or 2-propyl), butyl (e.g. tert-butyl), pentyl, hydroxylbutyl, hydroxylpropyl, glycerol, citrate, or glycol.
- alkyl moiety for example, comprising one to twelve carbons, for example, methyl, ethyl, propyl (e.g. n-propyl or 2-propyl), butyl (e.g. tert-butyl), pentyl, hydroxylbutyl, hydroxylpropyl, glycerol, citrate, or glycol.
- the BHB analog is a polymer of BHB or a polymer of a BHB analog.
- polymeric BHB which is a polymeric ester between the carboxyl group of BHB and the hydroxyl group of BHB. Hydrolysis of polymeric BHB, for example in the gastrointestinal tract, either chemically, enzymatically or mediated by microorganisms, may lead to release of monomeric BHB and uptake into circulation.
- the therapeutic composition of the invention comprises a BHB prodrug, or BHB analog prodrug.
- a BHB prodrug, or BHB analog prodrug is a composition comprising a cleavable promoiety conjugated to BHB, or a BHB analog.
- the promoiety is cleaved by enzymatic or chemical action to release the BHB, or BHB analog.
- the promoiety is joined to the BHB or BHB analog by ester linkage to the 1 and/or 3 carbon.
- the BHB analog comprises 3-hydroxybutyl 3-hydroxybutyrate, as described in U.S. Pat. No. 10,051,880, Hydroxybutyrate ester and medical uses thereof, by Clarke and Veech.
- the BHB analog comprises R,S-1,3-butanediol acetoacetate, for example, as described in U.S. Pat. No. 9,795,590, Ketone supplements for treatment of angelman syndrome, by Weeber et al.
- the BHB analog is an oligomer of (R)-3 -hydroxybutyrate, for example, as described in U.S. Pat. No. 10,559,258, Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives, by Veech and King.
- the BHB analog may comprise a composition described in U.S. Pat. No. 10,376,528, Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor, by Schmidt or in U.S. Pat. No. 5,693,850, Nutritive water soluble glycerol esters of hydroxy butyric acid, by Birkhahn et al..
- BHB is a chiral composition having two enantiomers: D- ⁇ -hydroxybutyric acid (also known as R- ⁇ -hydroxybutyric acid) and L- ⁇ -hydroxybutyric acid (also known as S- ⁇ -hydroxybutyric acid).
- the D- and L-forms of BHB are determined by the tetrahedral orientation of the hydroxyl group (or oxy group, in BHB esters) on the third carbon of BHB.
- D-BHB is the most common endogenous form of BHB.
- L-BHB is only occurring in small amounts in cells, and thus is metabolized or cleared at a slower rate, while retaining key signaling properties of endogenous D-BHB.
- BHB or a “BHB analog” made herein will be understood to encompass any mixture of D-BHB and L-BHB isoforms, unless the proportion of the enantiomers is specifically specified.
- Exemplary mixtures of enantiomers include substantially pure formulations of D-BHB and D-BHB analogs, for example, formulations comprising at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% D-BHB or a D-BHB analog.
- the mixture of enantiomers may comprise a substantially pure formulation of L-BHB or a L-BHB analog, for example, formulations comprising at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% L-BHB or L-BHB analog.
- the percentage of D-BHB or D-BHB analog in the mixture may be at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% (racemic mixture), 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the ketonic compositions of the invention will comprise an activator of GPR109A.
- GPR109A also known as hydroxycarboxylic acid receptor 2 (HCA2), and niacin receptor 1 (NIACR1 in humans) is a hydroxycarboxylic acid receptor.
- GPR109A is encoded by the HCAR2 gene.
- a GPR109A agonist or activator is a composition which activates, i.e. increases the activity of, GPR109A.
- GPR109A activation is indicated by a reduction in intracellular cAMP concentration.
- GPR109A activation is indicated by a reduction in lipolysis.
- GPR109a Activation of GPR109a occurs when a ligand or agonist binds to this receptor and causes a conformational change that then leads to activation of an associated heterotrimeric G-protein, in this case typically a G i /G 0 -type G protein.
- the activated G protein then regulates subsequent intracellular signaling pathways such as the inhibition of adenylate cyclase leading to lowering of the intracellular cAMP concentration.
- the GPR109A agonist is an exogenous ketone.
- the inventors of the present disclosure have unexpectedly determined that ketones present in ketosis have GPR109A activation activity and that this activity underlies various beneficial processes and effects of dietary ketosis.
- the exogenous ketone is BHB or BHB analog, as described above.
- the GPR109A agonist is a non-ketone.
- the GPR109 agonist is niacin, or a niacin analog such as inositol nicotinate. It will be understood that niacin in small doses is not sufficient to significantly activate GPR109A, and that dosage forms of less than the minimal dose, or doses administered at less than the minimal activation dose will not be considered GPR109A activators.
- the niacin or niacin mimic is provided (e.g.
- a dosage form) or administered in a biologically or therapeutically effective amount being an amount sufficient to significantly activate GPR109A, for example, in various embodiments being at least 100 mg, 250 mg, at least 500 mg, at least 750 mg, at least 1 gram, or at least 1.5 gram, for example, in human subjects.
- niacin provided or administered in a biologically or therapeutically effective amount comprising a megadose suitable for activation of GPR109A, for example, a dosage form or a daily administration of, for example 1 to 6 grams daily.
- the GPR109A agonist may be any of the following, as well as variants, derivatives, and polymorphs of the following.
- the GPR109A agonist is GSK256073, for example, as described in Specher et al., 2015, Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist, Eur J Pharmacol 756: 1-7.
- HCA2 non-flushing hydroxy-carboxylic acid receptor 2
- the GPR109A agonist is selected from the group consisting of (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903), monomethylfumarate acipimox, acifran, 3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4- carboxylic acid pyrazine-2-carboxylic acid, LUF6281 and LUF6283, and a pyrazolyl propionyl cyclohexenamide, for example, as described in Ding et al., 2010, Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A, Bioorg Med Chem Letters 21: 2721-2724; Palani et al., Discovery of SCH 900271, a Potent Nico
- Additional GPR109 agonists include compositions described in PCT International Patent Application Publication Number WO2008051403, Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A, by Beresis and Colletti; U.S. Pat. No. 7,723,342, Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia, by Palani et al.; United States Patent Application Publication Number US20090062269, Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment, by Raghavan et al.
- the GPR109A agonist is 5-[3-(1-methylcyclopropyl)propyl]-1H,2H,3H,4H,7H-pyrano[2,3-d]pyrimidine-2,4,7-trione, also known as SCH900271, a nicotinic acid derivative known in the art for the treatment of dislipideima.
- the GPRO19 agonist is (4aR,5aR)-4,4a,5,5a-Tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2]pyrazole-3-carboxylic acid, also known as MK1903.
- ketonic composition encompasses “one or more” ketonic agents, for example, one ketonic agent or a combinations of two or more difference ketonic agents. Combinations of different ketonic agents may be utilized, for example having different ADMET properties or physiological effects, in order to optimize the delivery, distribution, and action of ingested or administered products or to broaden the therapeutic effects thereof.
- the inventors of the present disclosure have advantageously determined that the efficacy of ketonic compositions such as BHB, BHB analogs, and GPR109A agonists is dramatically, and synergistically, enhanced when the agent is combined with a crystal precipitation inhibiting agent.
- the crystal precipitation inhibiting agent encompasses any agent that acts to inhibit the in vivo formation of crystals such as calcium or uric acid crystals. As is discussed below, in various contexts, crystal formation may be pathological or may promote pathological outcomes, for example, in the kidney.
- the scope of the invention encompasses a novel combination product comprising a ketonic composition and a crystal precipitation inhibitor, e.g. BHB or a BHB analog (such as a BHB precursor) in combination with the crystal precipitation inhibitor.
- a crystal precipitation inhibitor e.g. BHB or a BHB analog (such as a BHB precursor) in combination with the crystal precipitation inhibitor.
- the scope of the invention encompasses methods of supporting health, e.g. renal health, or treating an enumerated condition (e.g. a renal or cystic condition, e.g., PKD) by the administration of a biologically or therapeutically effective amount of the combination product.
- the crystal precipitation inhibitor composition may comprise any agent that inhibits the formation of crystals in physiological contexts, for example, the formation of calcium oxalate crystals, the formation of calcium phosphate crystals, and the formation of uric acid crystals.
- the crystal precipitation inhibitor is a calcium chelator.
- the crystal precipitation inhibitor composition is a buffering agent or pH-modulating agent that changes pH to inhibit crystal precipitation, for example, a pH-raising agent which inhibits uric acid crystal formation.
- the crystal precipitation-modulating composition is citrate.
- Citrate as referred to herein, encompasses citric acid itself, or salts and esters of citric acid.
- citrate may comprise a mono-, di- or tri-valent salt of citrate with sodium, potassium, magnesium, calcium, other cations, or mixtures of cations, or mixtures of citric acid with citrate salts.
- citrate may comprise a mono-salt, for example a mono-sodium salt, for example, the sodium salt of STRUCTURE 4, or other salts wherein a different cation is used:
- the scope of the invention encompasses a novel combination product comprising a ketonic composition and citrate, e.g. BHB or a BHB analog (such as a BHB precursor) in combination with citrate.
- a ketonic composition e.g. BHB or a BHB analog (such as a BHB precursor) in combination with citrate.
- the scope of the invention encompasses methods of supporting health, e.g. renal health, or treating an enumerated condition (e.g. a renal or cystic condition, e.g., PKD) by the administration of a biologically or therapeutically effective amount of the combination product comprising BHB or a BHB analog an citrate.
- Citrate may be administered as a salt of magnesium, potassium, calcium, sodium, or other forms.
- the crystal precipitation-modulating composition is a citrate analog, for example, a composition having structural similarity to citrate and retaining the crystal precipitation-modulating properties of citrate.
- Exemplary citrate analogs include derivatives of citric acid known in the art.
- Exemplary citrate analogs include esters of citric acid (e.g. monoester, diester, triester), amides of citric acid, 1,3 dioxal-4-ones, sidophores, peroxycitric acid, hydroxycitrate, and tricarballylic acid.
- Exemplary citrate analogs include compositions described in Milewska, 1988, Citric Acid, its natural and synthetic derivatives, Z Chem 28: 204-211.
- the crystal precipitation inhibitor is a composition that alkanizes urine, such as a carbonate or bicarbonate composition, such as magnesium carbonate or bicarbonate, calcium carbonate or bicarbonate, or sodium carbonate or bicarbonate.
- the crystal precipitation-modulating composition is a compound that can decrease the level of uric acid in the urine and may be used to treat hyperuricemia. Such compounds will decrease the risk of formation or uric acid crystals.
- Three examples are allopurinol, oxypurinol and febuxostat, inhibitors of xanthine oxidase, that act on purine catabolism, reducing the production of uric acid.
- Another example is Lesinurad which inhibits the function of transporter proteins involved in renal uric acid reabsorption (uric acid transporter 1 [URAT1] and organic anion transporter 4 [OAT4]), and lowers serum uric acid levels.
- uric acid transporter 1 [URAT1] and organic anion transporter 4 [OAT4] Another example is Rasburicase, a recombinant urate-oxidase enzyme, which converts uric acid to allantoin (an inactive and soluble metabolite of uric acid).
- the therapeutic compositions of the invention comprise a combination of a ketonic composition, e.g., one or more of BHB, a BHB analog, and/or a GPR109A activator, in combination with one or more crystal precipitation-modulating compositions, for example, a combination of BHB and citrate, for example an admixture of the two in a capsule, tablet, powder, beverage, or edible item
- a ketonic composition e.g., one or more of BHB, a BHB analog, and/or a GPR109A activator
- crystal precipitation-modulating compositions for example, a combination of BHB and citrate, for example an admixture of the two in a capsule, tablet, powder, beverage, or edible item
- the combination product is provided with the ketonic composition and crystal precipitation inhibitor as two separate dosage forms, optionally packaged in a single package.
- two separate tablets, capsules, powders e.g. a BHB capsule and a citrate capsule, may be provided with instructions to take them at the same time.
- the recipient may benefit from the synergistic therapeutic properties but advantageously has the option to modify the individual doses according to specific needs.
- citrate is a common additive to dietary supplements and other food items.
- sodium citrate or potassium citrate are known additives used as flavoring agents, preservatives, and pH buffers.
- the quantity of citrate used for such purposes is therapeutically insignificant.
- the scope of the invention encompasses synergistic combination products comprising citrate wherein the quantity of citrate is biologically effective, i.e. sufficient to inhibit crystal precipitation in vivo, for example, crystal precipitation in the kidney.
- the biologically effective dosage may be in the range of 100 mg to 10 grams citrate per day.
- the citrate dose is about or at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 mg citrate or citrate salt per dose, per dosage form, or cumulative dosing per day.
- the dose may be in the range of 0.1 mmol- 10 mmol citrate/100 g body weight per dosage, or per day, for example, a dosage of about or at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2. 2.3, 2.4, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10 mmol citrate/100 g body weight per dose, or cumulative dose per day.
- the citrate dosage is in the range of 0.1 to 10 mg citrate or citrate salt per m 2 body area per dosage or per day, for example at being about or at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5., 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 or 10 mg per m 2 body area.
- the biologically effective citrate is defined in terms of its abundance relative to the co-administered ketonic agent, e.g. BHB or a BHB analog.
- the ratio of citrate molecules, or mass of citrate, to BHB or BHB analog molecules (or mass) is in the range of 1:10 to 10:1.
- Exemplary ratios of citrate to BHB or BHB analog are in the range of 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.
- the amount of citrate in the combination product is described in terms of the weight percentage of citrate in the combination product.
- the weight percentage of citrate is calculated as proportional mass of citrate to the mass of citrate and the one or more ketonic compositions (e.g. the weight percentage of citrate with respect to active ingredients only).
- the weight percentage of citrate may be in the range of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%.
- the weight percentage of citrate is calculated as the proportional mass of citrate to the mass of the entire formulation, including citrate, ketonic compositions, and carriers and other inert ingredients (e.g. the weight percentage of citrate with respect to the entire product).
- the weight percentage of citrate may be in the range of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%.
- the scope of the invention encompasses novel compositions, advantageously comprising a bi-functional molecule comprising one or more ketonic compositions, e.g. one or more of BHB, a BHB analog, or a GPR109A agonist, conjugated to one or more molecules of a crystal precipitation-modulating agent.
- the dietary supplements and therapeutic compositions of the invention comprise such compositions.
- the use of such compositions advantageously provides a ketosis mimic and/or GPR109A agonist in combination with a crystal precipitation inhibitor in a single composition, at a desirable stoichiometric ratio.
- the bi-functional molecules may be designed to be neutral or less acidic, thereby avoiding or reducing the need for salt formulation.
- the bi-functional molecule comprises a BHB-citrate ester, comprising one or more BHB molecules and/or one or more a BHB analog molecules conjugated to citrate.
- BHB-citrate esters include STRUCTURE 5:
- R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is ketonic composition.
- R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is BHB.
- R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is a BHB analog.
- R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is 1,3 butanediol.
- R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is a GPR109A activator.
- Exemplary bi-functional molecules include Structure 6:
- the bi-functional BHB-citrate esters and like composition of the invention may be synthesized according to known methods for the esterification of citrate and like molecules.
- Fischer-Speier esterification may be employed by refluxing citric acid with an excess of 1,3-butanediol in the presence of an acid catalyst such as sulfuric acid.
- an acid catalyst such as sulfuric acid.
- Such a reaction is expected to yield a mixture of structures 7 and 8 as well as mixed esters with the 1,3-butanediol component esterified variously via the 1 and 3 positions in addition to other possible combinations.
- the in vivo hydrolysis of the bi-functional esters is expected to yield the functional components citrate and 1,3-butanediol.
- compositions and methods of the invention encompasses a combination product comprising a ketonic composition, e.g., one or more of BHB, a BHB analog, and/or a GPR109A activator, and a lipotoxic agent.
- the lipotoxic agent may comprise any fatty acid or other composition which create toxicity for cells that are dependent upon glucose for energy production and may be defective in beta-oxidation of fatty acids, i.e. having enhanced sensitivity to lipotoxicity from lipids that accumulate but which cannot be metabolized.
- Exemplary glucose dependent cells include cyst epithelial cells, including PKD cyst epithelial cells and liver cyst epithelial cells, and cancer cells.
- the lipotoxic composition is an MCT, as described above.
- MCTs include triglycerides comprising six to 12-carbon chains, including caproic acid, caprylic acid, capric acid, and lauric acid.
- unsaturated fatty acids may act as lipotoxic agents for glucose-dependent cells.
- exemplary unsaturated fatty acids include monounsaturated and polyunsaturated fats such as a-Linolenic acid, Stearidonic acid, Linoleic acid, Linolelaidic acid, ⁇ -Linolenic acid, Palmitoleic acid, Vaccenic acid, Oleic acid.
- Such unsaturated fatty acids may be administered alone or in mixtures as free fatty acids or their salts or as triglycerides.
- these unsaturated fatty acids may be administered in the form of natural fats and oils that are rich in these unsaturated fatty acids, for example including oils from flaxseed, walnuts, chia, hemp, and other vegetable oils.
- the lipotoxic agents advantageously compositions that can be taken orally and which are used in various food products and supplements.
- the lipotoxic agents are included in dietary supplements of the invention.
- the dosage of lipotoxic agents will be in the range of 0.5-100 g per day, for example about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 90 g per day. .
- the combination product comprising a ketonic composition and a lipotoxic composition further includes a crystal precipitation-modulating agent (e.g. citrate).
- a crystal precipitation-modulating agent e.g. citrate
- the combination product may comprise BHB (or a BHB analog) in combination with citrate (or a citrate analog) in combination with one or more lipotoxic compositions, representing a tri-functional agent.
- compositions described herein may be formulated in various ways for effective and controlled delivery. It will be understood that the compositions may comprise the active agents described herein in combination with any number of ingredients that facilitate effective ingestion, administration, delivery, adsorption, distribution, and metabolism of the active agents. In various embodiments, the compositions described herein comprise dietary supplements, or therapeutic compositions (including therapeutic compositions formulated as dietary supplements).
- compositions described herein containing or comprising ketonic agents may be considered “medicaments.”
- act of manufacturing, including formulating, ketonic agents into dietary supplements, therapeutic compositions, or any ingested or otherwise administered compositions will be presumed to be performed under any specified processes therefor, and if no process is specified, then the act of manufacture, including formulation, will be assumed to be achieved by standard means known in the art.
- choice of any described compositions wherein ketonic compositions are included, will be presumed to encompass an implied method of making such medicaments.
- the ketonic composition (e.g. BHB, BHB analog, and/or GPR109A activator) is formulated as a salt.
- Pharmaceutical salt formulations are known in the art and may impart higher solubility, stability, and bioavailability to the therapeutic molecules.
- Exemplary salts include salts of amino acids, alkali metals, alkaline earth metals, transition metals, for example: arginine salts, calcium salts, chromium salts, citrulline salts, cobalt salts, copper salts, creatine salts, glutamine salts, histidine salts, iron salts, isoleucine salts, leucine salts, lithium salts, lysine salts, magnesium salts, manganese salts, molybdenum salts, ornithine salts, potassium salts, selenium salts, sodium salts, and zinc salts.
- arginine salts calcium salts, chromium salts, citrulline salts, cobalt salts, copper salts, creatine salts, glutamine salts, histidine salts, iron salts, isoleucine salts, leucine salts, lithium salts, lysine salts, magnesium salts, manganese salts, molybdenum salts, or
- the ketonic agents of the invention are formulated in a low-salt or zero-salt formulation, to avoid stressing the body, especially the kidneys, of the recipient.
- a low-sodium and low-potassium and low-calcium formulation may comprise a formulation that would lead to an added sodium or potassium or calcium intake of no more than 500 mg/day each, preferably less.
- the ketonic compositions of the invention may be formulated for efficient delivery by a selected route.
- the ketonic compositions of the invention may be formulated in combination with pharmaceutically acceptable excipients, carriers, diluents, release formulations and other drug delivery or drug targeting vehicles, as known in the art.
- the ketonic compositions of the invention are amenable to efficient oral delivery and may be formulated therefor.
- Oral formulations may include any number of fillers, flavoring agents, coloring agents, sweeteners, and other compositions used in the art for oral delivery of agents.
- the pharmaceutical composition is formulated for oral delivery in tablets or capsules.
- the pharmaceutical composition is formulated as a powder to be mixed with liquid.
- the ketonic composition is formulated as a liquid containing the therapeutic agent, i.e. solutions, such as water or other flavored drinks containing BHB or a BHB analog.
- the ketonic compositions of the invention are formulated for administration via non-oral routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal delivery.
- the ketonic compositions of the invention may be formulated for microbubble delivery for example, ultrasound meditated microbubble delivery, for site-specific delivery.
- the ketonic compositions comprises nanoparticles containing or functionalized with the selected active agent of the ketonic composition, for delivery by nanoparticle-based delivery methods.
- the ketonic composition comprises the selected therapeutic agent admixed with a polymeric material for timed release elution of the agent or to prevent premature digestion of the material in the digestive tract.
- the ketonic composition comprises chemically conjugated magnetizable particles or use in magnetic-directed drug delivery methods, as known in the art.
- the ketonic composition of the invention is coated onto an implant or drug eluting device.
- the therapeutic composition of the invention comprises a targeting moiety that facilitates delivery to a target cell type or organ, such as the kidneys, liver, cysts, or other sites.
- a targeting moiety that facilitates delivery to a target cell type or organ, such as the kidneys, liver, cysts, or other sites.
- the ketonic composition of the invention is conjugated to a polymeric immunoglobulin such as a polymeric IgM or IgA.
- Such agents may be efficiently targeted to renal cysts, for example, cysts present in the case of polycystic kidney disease.
- the various methods of the invention may encompass the administration of an agent to a subject.
- Administration may encompass the act of providing the agent to the subject or actually introducing the agent into the subject.
- Administration as used herein will encompass self-administration.
- dietary supplements are ingested by a subject. Such ingestion will be considered administration, i.e., self-administration of the enumerated composition.
- Administration may also comprise provision of a selected composition to the subject, for example, providing food or liquids that contain the composition to an animal.
- the ketonic composition is formulated and administered as a dietary supplement.
- a dietary supplement is a composition that is administered orally, for example, in food or drink, with food or drink, or which otherwise supplements the regular intake of food. From a regulatory standpoint, a dietary supplement is generally a composition that can be purchased and used without a prescription.
- a dietary supplement is “a product intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any ingredient just described.”
- the dietary supplements of the invention may encompass any formulation for oral delivery.
- the ketonic compositions of the invention are ingested in liquids, for example, being formulated in any number of beverage formats, including infused water, sports drinks, energy drinks, teas, fruit juices, or meal replacement beverages.
- the ketonic compositions of the invention are formulated as a powder which may be dissolved in water, or other drinks such as fruit juice, coffee, or tea.
- the powder is packaged in individual packets or vials at a measured dose.
- the powder is packaged with a scoop which measures the correct dose for mixing with liquid and instructions for doing so at a specified frequency.
- the dietary supplement of the invention is formulated as a capsule, tablet, or chewable tablet.
- the dietary supplements of the invention are ingested as a component of an edible item, for example, being incorporated into gummies, cookies, snack bars, meal replacement bars and other bars, cereals, biscuits, crackers, confectionery items, and probiotic formulations including yogurt, and other food items.
- the dietary supplements of the invention are formulated as products for non-human animals, such as chow, feed, treats or snacks, or supplemented pet food.
- the dietary supplements are preferably formulated as a single product containing both the ketonic composition (e.g. BHB or BHB analog) and the secondary agent so that only a single product is required to be digested.
- a secondary agent e.g. a crystal precipitation inhibitor such as citrate or a lipotoxic agent such as unsaturated fatty acids
- the dietary supplements are preferably formulated as a single product containing both the ketonic composition (e.g. BHB or BHB analog) and the secondary agent so that only a single product is required to be digested.
- the scope of the invention includes separate formulations and dosage forms of the ketonic composition and secondary agents, to be ingested separately.
- the scope of the invention encompasses numerous methods directed to the use of ketonic compositions for the maintenance of health, prevention of disease, and in therapeutic applications.
- the scope of the invention encompasses methods of using dietary supplements comprising ketonic compositions for supporting health.
- the scope of the invention encompasses the use of ketonic compositions in therapeutic methods for the prevention and treatment of various diseases and pathological conditions.
- ketonic compositions by, and administration of ketonic compositions to, subjects.
- the subject may be a human subject, for example, in some contexts, a patient.
- the subject may comprise a non-human animal of any species, including test animals, veterinary subjects, pets, and livestock, for example, any of mice, rats, dogs, cats, sheep, goats, cows, pigs, horses, camels, non-human primates, or other animals.
- polycystic kidney disease is prevalent in dogs and cats.
- the subject of the method will be a subject in need of treatment for a selected condition.
- the subject may be a subject suffering from a condition, may be symptomatic of a selected condition, or may be at risk of a selected condition.
- a biologically or therapeutically effective amount is an amount of ketonic agent ingested as dietary supplement or administered therapeutically that is sufficient to induce a ketonic response.
- a response may be indicated by assaying the elevated blood concentration of a ketone body such as BHB.
- a response could also be measured by assaying a change in the blood levels of fatty acids that can be used as an indicator of the anti-lipolytic consequences of GPR109a activation.
- a ketonic response is the elevation of ketones in the blood or other compartment of the subject, for example, any significant elevation compared to subjects not experiencing ketosis.
- a ketonic response is the increase in GPR109A activation in selected target cells of the subject, for example, any significant increase in GPR109A activity compared to subjects not ingesting or administered a ketonic agent.
- a ketonic response is the attainment of a specific physiological outcome or state, for example, the mean or median dosage required to attain the selected outcome in a significant portion of representative subjects, compared to subjects not ingesting or administered the ketonic agent.
- Selected outcomes may encompass any relevant outcome, such as reduced symptoms of a selected condition, for example, reduced size or abundance of cysts in the case of cystic disease, improved organ or cellular function, and other physiological or health measures.
- the dietary supplements and therapeutic ketonic agents of the invention are ingested or administered in a dose, being an amount of ketonic composition ingested or otherwise received at a time or over a specified timeframe (e.g. a daily dose). Doses may be referred to as approximate amounts, for example, being “about X mg.” “About,” as used herein means, in various embodiments, within plus-or-minus 10%, plus-or-minus 5%, or plus-or-minus 1% of the enumerated value.
- the ingested or administered ketonic composition is BHB, or a BHB analog, e.g. a BHB precursor, configured for oral administration, wherein the administration is oral, and the biologically effective or therapeutically effective dosage is in the range of 0.1 to 50 grams BHB per day, e.g., for humans.
- daily doses of about or at least 100 mg, about or at least 250 mg, about or at least 500 mg, about or at least 1 gram, about or at least 2 grams, about or at least 3 grams, about or at least 4 grams, about or at least 5 grams, about or at least 6 grams, about or at least 7 grams, about or at least 8 grams, about or at least 9 grams, about or at least 10 grams, about or at least 12 grams, about or at least 15 grams, or about or at least 20 grams may be ingested or administered.
- the dosage of BHB, BHB analog, including BHB precursors is in the range of 10-200 mg/Kg body weight, for example, 10, 25, 50, 75, 100, 125, 150, 175, or 200 mg./Kg.
- the exemplary dosages above may be adjusted based on the difference in body weight or body surface area.
- the non-human is a small animal (e.g. rodent, dog, or cat) and the biologically or therapeutically effective amount of BHB or BHB analog is in the range of 10-150 mg/Kg, in various embodiments, for example, being about 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 100, 120, 150 mg/Kg.
- the biologically effective or therapeutically effective amount of BHB or BHB analog is determined as the amount necessary to raise blood ketone levels (e.g., BHB levels) to a selected threshold indicative of ketosis, for example, a dose sufficient to attain a blood concentration of BHB at least 0.250 to 5 mMol BHB per liter of blood, for example, about or at least 0.250, about or at least 0.500, about or at least 0.750, about or at least 1.0, about or at least 2.0, about or at least 3.0 mMol BHB per liter of blood.
- blood ketone levels e.g., BHB levels
- a selected threshold indicative of ketosis for example, a dose sufficient to attain a blood concentration of BHB at least 0.250 to 5 mMol BHB per liter of blood, for example, about or at least 0.250, about or at least 0.500, about or at least 0.750, about or at least 1.0, about or at least 2.0, about or at least 3.0 mMol BHB per
- the biologically or therapeutically effective dose will be determined by the potency, ADMET, and delivery route of the selected GPR109A activator.
- This class of compositions includes potent small molecules that act in the picomolar to nanomolar range, as well as ketones and other orally available compositions (e.g. niacin) that require higher concentrations to induce GRP109A activation in selected target cells (e.g. cyst epithelial cells).
- the biologically or therapeutically effective dose of GPR109A activator may be determined by one of skill in the art based on the properties of the agent and the desired therapeutic outcome.
- a biologically or therapeutically effective amount is an amount of crystal precipitation inhibitor ingested or administered that is sufficient to inhibit crystal formation in vivo, e.g. uric acid crystal formation or calcium crystal formation, or sufficient to induce conditions that inhibit crystal formation, such as increased urinary concentration of citrate to antagonize calcium crystal precipitation, or increased urinary pH to antagonize uric acid crystal precipitation, or reduced blood or urine levels of uric acid to antagonize uric acid crystal precipitation.
- the selected crystal precipitation inhibitor for example, citrate
- the administration is oral, and, for example in humans, the biologically or therapeutically effective dose ingested or administered may be in the range of 100 mg to 15 grams, for example, at least or about 100 mg, at least or about 200 mg, at least or about 300 mg, at least or about 500 mg, at least or about 1 gram, at least or about 2 grams, at least or about 3 grams, at least or about 4 grams, at least or about 5 grams, at least or about 6 grams, at least or about 7 grams, at least or about 8 grams, at least or about 9, grams, or at least or about 10 grams.
- the dosage of citrate or citrate analog is in the range of 5-100 mg/Kg body weight, for example, in various embodiments, being 5, 10, 20, 25, 30, 40, 50, 55, 65, 70, 75, 80, 85 90, or 100 mg/Kg.
- the exemplary dosages above may be adjusted based on the difference in body weight or body surface area.
- the non-human is a small animal (e.g.
- rodent, dog, or cat and the biologically or therapeutically effective amount of citrate or citrate analog is in the range of 10-100, for example, 25-75 mg/Kg, in various embodiments, for example, being about 10, 20, 30, 40, 45, 50, 55, 60, 65, 70, 80, 90 or 100 mg/Kg.
- the dosage of the crystal precipitation inhibitor, e.g., citrate, in the dietary supplement may be determined by alternate measures.
- the crystal precipitation inhibitor such as citrate
- the crystal precipitation inhibitor is ingested or administered at a dosage of between 0.1 mmol- 10 mmol/100 g body weight per day, for example, at least 0.5, at least 1, at least 2, at least 5, at least 7.5 or at least 10 mmol/100 g body weight per day.
- the crystal precipitation inhibitor such as citrate
- the crystal precipitation inhibitor is ingested or administered at a dosage of between 0.5 to 10 mg/citrate or citrate salt per m 2 body area per day, for example at least 1, at least 2, at least 3, at least 4, or at least 5 mg per m 2 body area, per day.
- Doses may be ingested or administered according to a selected health or treatment regimen.
- doses are ingested or administered for a selected period of time, e.g. a period of days, weeks, or months.
- chronic, long-term ingestion or administration is contemplated for maintaining beneficial, therapeutic, or preventative effects.
- the administration is daily with one or more dosages ingested or administered per day.
- dosages may be administered during the day, to arrive a cumulative dosage near, at, or above the biologically effective or therapeutically effective daily dosage, for example, two, three, four, or more doses per day.
- Dosage forms e.g. capsules, packets of dissolvable powder for drinks, scoops for measuring such powder, etc.
- two or more dosages are delivered per day, for example, a morning and an evening dose, a dosage administered before or after each meal, a dosage delivered every four hours, six hours, twelve hours, or at other selected time intervals.
- a low dosage of BHB administered multiple times per day, may be more palatable than a full daily dosage, wherein the unpleasant taste of BHB is an issue.
- the dietary supplement is consumed at less than daily frequency, for example, once a week, twice a week, three times a week, etc.
- the methods of the invention will encompass the administration or ingestion of ketonic compositions in a dietary supplement or a therapeutic composition.
- the dietary supplement or therapeutic composition may comprise any of the ketonic compositions, combination products, and formulations, as disclosed in the previous sections,
- the dietary supplement or a therapeutic composition comprises an exemplary formulation as forth below.
- the dietary supplement or a therapeutic composition will comprise a ketonic composition.
- the ketonic composition may comprise one or more of BHB, a BHB analog, a GPR109A agonist, or a combination of the foregoing.
- the formulations may comprise a combination of two or more different ketonic compositions.
- ketonic composition comprises a BHB analog, wherein the BHB analog may comprises an ester of BHB, a BHB precursor, 1,3-butanediol, or a bi-functional composition comprising one or more molecules of BHB, a BHB analog, and/or a GPR109A agonist conjugated to one or more molecules of citrate.
- the bi-functional molecule is Structure 5, Structure 6, Structure 7, or Structure 8.
- the composition comprises L-BHB, for example, at least 10% L-BHB, about 50% L-BHB, or substantially pure L-BHB.
- the ketonic composition comprises a GPR109A agonist, wherein the GPR109A agonist comprises a composition selected from the group consisting of niacin, a niacin analog, clotrimazole, GSK256073, MK-1903, monomethylfumarate acipimox, acifran, 3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4-carboxylic acid pyrazine-2-carboxylic acid, LUF6281, LUF6283, a pyrazolyl propionyl cyclohexenamide, an acyl hydroxypyrazole, and SCH900271.
- the dietary supplement or therapeutic composition will comprise a ketonic composition in a biologically or therapeutically effective amount.
- the biologically or therapeutically effective amount is an amount sufficient to attain blood ketone levels at a level indicative of ketosis, for example, a dose sufficient to attain a blood concentration of BHB at least 0.250 to 5 mMol BHB per liter of blood, for example, about or at least 0.250, about or at least 0.500, about or at least 0.750, about or at least 1.0 mMol BHB per liter.
- the ketonic agent comprises BHB and the biologically or therapeutically effective amount is an amount in the range of 0.1 to 50 grams BHB, for example, 0.1 to 50 grams BHB per day.
- the biologically or therapeutically effective amount is about or at least 100 mg, about or at least 250 mg, about or at least 500 mg, about or at least 1 gram, about or at least 2 grams, about or at least 5 grams, or, about or at least 10 grams.
- the dietary supplement or therapeutic composition will comprise a ketonic composition in combination with a biologically or therapeutically effective amount of a crystal precipitation inhibitor.
- the biologically or therapeutically effective amount of a crystal precipitation inhibitor is an amount sufficient to inhibit in vivo crystal precipitation, for example, sufficient to inhibit the formation of calcium oxalate crystals, the formation of calcium phosphate crystals, and/or the formation of uric acid crystals.
- the crystal precipitation inhibitor is a calcium chelator.
- the crystal precipitation inhibitor is a buffering agent or pH-modulating or alkanizing agent.
- the crystal precipitation inhibitor is selected from the group consisting of citrate, hydroxycitrate, esters of citric acid (e.g. monoester, diester, triester), amides of citric acid, 1,3 dioxal-4-ones, sidophores, peroxycitric acid, hydroxycitrate, and tricarballylic acid, a composition that alkanizes urine, a carbonate or bicarbonate, magnesium carbonate or bicarbonate, calcium carbonate or bicarbonate, or sodium carbonate or bicarbonate, allopurinol, oxypurinol and febuxostat, inhibitors of xanthine oxidase, Lesinurad, Rasburicase, and a calcium chelator.
- citric acid e.g. monoester, diester, triester
- amides of citric acid 1,3 dioxal-4-ones
- sidophores peroxycitric acid
- hydroxycitrate hydroxycitrate
- the crystal precipitation inhibitor is citrate.
- the biologically effective biologically or therapeutically effective amount is at least 100 mg citrate, for example, 200 mg citrate per day, at least 500 mg citrate, for example, 500 mg citrate per day, citrate at a weight percentage in the dietary supplement or therapeutic composition of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
- the dietary supplement or therapeutic composition will comprise a ketonic composition in combination with a biologically or therapeutically effective amount of a lipotoxic agent.
- the biologically or therapeutically effective amount of a lipotoxic agent is an amount sufficient to cause lipotoxic effects in glucose-dependent cells, e.g., PKD cyst epithelial cells.
- biologically or therapeutically effective amount of a lipotoxic agent is in the range of 0.5-100g per day, for example about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 90 g per day.
- the lipotoxic agent comprises MCT.
- the lipotoxic agent comprises fatty acids.
- the dietary supplement or therapeutic composition comprises a ketonic composition in combination with both a biologically or therapeutically effective amount of a crystal precipitation inhibitor and a biologically or therapeutically effective amount of a lipotoxic agent.
- the dietary supplements of the invention are by definition formulated for oral delivery.
- the therapeutic compositions may also be formulated for oral delivery.
- the therapeutic composition is formulated for oral delivery as a dietary supplement.
- the dietary supplement or therapeutic composition is formulated as a capsule, a chewable tablet, a tablet, a dissolvable powder, a beverage, or a food item.
- the dietary supplement or therapeutic composition may be formulated as a single product containing both the ketonic composition (e.g. BHB or BHB analog) and the secondary agent so that only a single product is required to be ingested or administered.
- the ketonic composition and the secondary agent(s) e.g. a crystal precipitation inhibitor such as citrate or a lipotoxic agent
- the ketonic composition and the secondary agent(s) are provided together in separate dosage forms, for example, capsules or chewable tablets, for example, to be ingested at the same time.
- the scope of the invention encompasses novel methods of promoting health and wellness by the use of dietary supplements comprising ketonic compositions.
- the function of the compositions and methods of the invention will be described as “supporting health,” for example, “supporting renal health.”
- supporting a enumerated type of health will encompass any activity that maintains, enhances, improves, or promotes relevant organ or cellular function, for example, renal function in the case of supporting renal health.
- the support of health is achieved by ameliorating the risk, progression, and/or severity of a condition.
- Ameliorating the risk, progression, and/or severity of a condition may encompass any number of physiological, health, or medical processes, such as treating or preventing the condition in any way, reducing, reversing, or curing symptoms, pathologies, or pathological processes of the condition, slowing or halting the progression of the condition, or any other therapeutic or beneficial effect.
- Certain methods of the invention encompass the prevention or treatment of a selected condition.
- treatment will encompass any number of therapeutic effects and outcomes with respect to a selected condition, including, for example: a reduction in the severity of symptoms of the condition; the inhibition of pathological processes underlying the condition; the reversal of pathological events or processes of the condition; halting or slowing the progression of the condition; or a reduction in morbidity and/or mortality associated with the condition.
- Treatment will further encompass prevention of an enumerated condition.
- prevention will encompass any number of actions with respect to a selected condition, for example: preventing the onset of the condition; reducing the probability of the condition occurring; halting the further progression of the condition, ameliorating underlying physiological parameters that promote the condition, or any other preventative action.
- treatment will further encompass enhancements of target cell or organ function, such as quantitatively or qualitatively improved function, for example, in certain implementations, improved function, restoring normal function, or maintaining function.
- the scope of the invention encompasses the use of ketonic compositions in dietary supplements and therapeutic compositions to address various aspects of renal health and renal conditions.
- the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting renal health in a subject.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of renal health.
- the scope of the invention encompasses a method of supporting renal health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition.
- the dietary supplement comprises a ketonic composition in combination with a crystal precipitation inhibitor and/or a lipotoxic agent.
- supporting renal health means maintaining or enhancing one or more measures of renal function.
- renal function may be assessed by glomerular filtration rate, creatine clearance rate, urine output, proteinuria, or other measures of renal function known in the art.
- supporting renal health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more renal conditions.
- the scope of the invention further encompasses the use of therapeutic compositions comprising ketonic compositions for the treatment of renal conditions.
- the scope of the invention encompasses a ketonic composition for use in a method of treating a renal condition.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of a renal condition.
- the scope of the invention encompasses a method of treating a renal condition in a subject in need of treatment therefor by administering to the subject a therapeutically effective amount of a ketonic composition.
- the ketonic composition may be delivered or provided in a therapeutic composition, for example, a formulation comprising other components and/or active ingredients.
- the dietary supplement comprises a ketonic composition in combination with a crystal precipitation inhibitor and/or a lipotoxic agent.
- the treatment is a preventative treatment.
- the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of renal health support, for example, a subject having or at risk of a renal condition.
- a renal condition as used herein, may encompass any pathological process, pathological state, disease, or dysfunction of the kidney.
- the subject is a human, a cat, or a dog.
- the renal condition is a cystic condition.
- the cystic condition is PKD.
- supporting renal health and/or treatment of a cystic conditions encompasses preventing or ameliorating any pathological effects of renal cysts, reducing or preventing the formation of renal cysts, reducing the number and/or size of renal cysts, slowing the growth rate of renal cysts, or eliminating renal cysts.
- the cystic condition is ADPKD.
- the polycystic kidney disease is autosomal recessive polycystic kidney disease (ARPKD).
- the subject to which the dietary supplement or therapeutic composition is administered is a subject having PKD or at risk of PKD.
- the subject at risk of PKD is a subject carrying a mutation in any of PKD1, PKD2, PKD3, or other genes wherein mutations increase the risk of PKD.
- the subject at risk of PKD is a subject with health or demographic factors associated with PKD risk.
- the subject is a human.
- the subject is a dog or cat.
- the renal cystic condition is a condition selected from the group consisting of renal cysts as found in tuberous sclerosis complex, medullary cystic kidney disease, Acquired Cystic Kidney Disease, including acquired simple renal cysts, cystic renal cell carcinoma, and cystic nephroma.
- the renal condition is acute kidney injury (AKI).
- AKI encompasses kidney dysfunction or failure, and may be caused by many factors or causative agents.
- AKI manifests as damage to kidneys and impaired kidney functions, including progression along the RIFLE staging criteria known in the art, encompassing risk, injury, failure, loss, and end-stage renal disease.
- the subject to which the dietary supplement or therapeutic composition is administered is a subject having or at risk of AKI.
- a subject at risk of AKI is a subject having systemic disease, trauma, sepsis, renal artery stenosis, renal vein thrombosis, urinary tract obstruction, glomerulonephritis, acute tubular necrosis, acute interstitial nephritis, or liver cirrhosis.
- a subject at risk of AKI is a subject having reduced blood flow to kidneys, such as by cardiac dysfunction or failure, surgery, trauma or ischemia.
- a subject at risk of having AKI is a subject likely to be exposed to or being exposed to harmful levels of nephrotoxins such as mercury or platinum compounds, radiological contrast agents, and antibiotics.
- the subject at risk of AKI is a subject likely to have or scheduled to have surgery, in one embodiment, cardiac surgery.
- dietary supplement and/or therapeutic composition is administered as a pre-treatment prior to surgery and/or post-treatment after surgery in order reduce the risk or severity of AKI and to reduce the risk of developing complications therefrom, including chronic kidney disease.
- the renal condition is chronic kidney disease (CKD), encompassing any gradual loss or long-term impairment of kidney function.
- the subject to which the dietary supplement or therapeutic composition is administered is a subject having or at risk of CKD.
- a subject at risk of CKD may be a subject having any known risk factor of CKD including, Type I or Type II diabetes mellitus, prior occurrence of acute kidney injury, glomerulornephritis, high blood pressure, or family history of CKD.
- the renal condition is a condition selected from the group consisting of: diabetic nephropathy, nephronophthisis, Meckel-Gruber syndrome, Bardet-Biedl syndrome, Joubert syndrome, medullary sponge kidney, multicystic dysplastic kidney, Dent's disease, Glomerulocystic kidney disease, Von Hippel-Lindau Syndrome, and mixed epithelial and stromal tumor of the kidney.
- IRI ischemic reperfusion injuries
- This class of pathologies is associated with the loss of blood flow in the affected organ, structure, or area.
- the hypoxia and loss of nutrients in the affected area promotes conditions wherein the subsequent restoration of circulation results in inflammation and damage caused by severe oxidative stress.
- the loss of circulation may be the result of trauma, injury, ischemic events, cardiac failure, or other causes.
- Surgery is also a causative agent of IRI, especially cardiac surgery, wherein reduced blood flow during the procedure facilitates IRI upon restoration of normal blood flow.
- IRI may affect any number of tissues, including the arteries and veins, brain, heart, liver, lungs, kidneys, skeletal muscle, and digestive tract.
- the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting health with regards to ischemic reperfusion injury.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of health with regards to ischemic reperfusion injury.
- the scope of the invention encompasses a method of supporting health with regards to ischemic reperfusion injury in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition.
- the dietary supplement may comprises a ketonic agent in combination with a crystal precipitation inhibitor.
- supporting health with respect to ischemic reperfusion injury means maintaining or enhancing one or more measures of organ function, for example, function of the brain, heart, liver, lungs, kidneys, skeletal muscle, or digestive tract.
- supporting health with respect to ischemic reperfusion injury in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more ischemic reperfusion injury conditions.
- the scope of the invention encompasses the use of therapeutic compositions comprising ketonic compositions for the treatment of ischemic reperfusion injury conditions.
- the scope of the invention encompasses a ketonic composition for use in a method of treating an ischemic reperfusion injury condition.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of ischemic reperfusion injury.
- the scope of the invention encompasses a method of treating a ischemic reperfusion injury condition in a subject in need of treatment therefor by administering to the subject a therapeutically effective amount of a ketonic composition.
- the ketonic composition may be delivered or provided in a therapeutic composition, for example, a formulation comprising other components and/or active ingredients.
- the therapeutic composition comprises a ketonic composition in combination with a crystal precipitation inhibitor.
- the treatment is a preventative treatment.
- the subject to which the dietary supplement or therapeutic composition comprising a ketonic composition is administered is a subject in need of treatment for one or more ischemic reperfusion injuries, in some embodiments being a subject that has experienced, or is at risk of the one or more ischemic reperfusion injuries.
- the subject at risk of ischemic reperfusion injury is a subject likely or scheduled to undergo surgery.
- the dietary supplement or therapeutic composition is administered as a pre-treatment prior to surgery.
- the methods of the invention are directed to maintaining or improving some aspect of neurological health, and to addressing neurological conditions, including conditions of the brain, central nervous system, and peripheral nervous system.
- the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting neurological health.
- the scope of the invention encompasses a method of supporting neurological health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a therapeutically effective amount of a dietary supplement comprising a ketonic composition.
- supporting neurological health means maintaining or enhancing one or more measures of neurological function, for example, cognitive function or motor function.
- supporting neurological health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more neurological conditions.
- the scope of the invention encompasses therapeutic compositions comprising a ketonic composition for use in a method of treating a neurological condition.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for treatment of a neurological condition.
- the scope of the invention encompasses a method of treating a neurological condition in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising a ketonic composition.
- the therapeutic composition further comprises a crystal precipitation inhibitor and/or a lipotoxic agent.
- the treatment is a preventative treatment.
- the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of treatment for one or more neurological conditions.
- a neurological condition may encompass any pathological process, pathological state, disease, or dysfunction of the central or peripheral nervous system, especially conditions that affect the brain, for example, a neurodegenerative disease.
- the subject at risk of a neurological condition is has, or is at risk of the one or more neurological conditions.
- the neurological condition is a neurodegenerative condition.
- the neurological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, chronic traumatic encephalopathy, age-related neurodegeneration, frontotemporal dementia, and retinitis pigmentosa.
- Cilia Health and Treating Ciliopathies.
- the methods of the invention are directed to health aspects and conditions associated with the cilia.
- Cilia are a component of almost all vertebrate cells.
- Ciliopathies encompass a large group of disorders associated with cilial dysfunction, typically driven by genetic mutations encoding defective proteins which result in either abnormal formation of cilia or which disrupt their normal function.
- Ciliopathies include a wide array of conditions across various organs and systems of the body.
- the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting cilial health.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of cilial health .
- the scope of the invention encompasses a method of supporting cilial health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition.
- supporting cilial health means maintaining or enhancing one or more measures of cilial function.
- supporting cilial health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more ciliopathies.
- the scope of the invention encompasses a therapeutic compositions comprising a ketonic composition for use in a method of treating a ciliopathy.
- the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of a ciliopathy.
- the scope of the invention encompasses a method of treating a ciliopathy in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising a ketonic composition.
- the therapeutic composition further comprises a crystal precipitation inhibitor and/or a lipotoxic agent.
- the treatment is a preventative treatment to a subject at risk of a ciliopathy.
- the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of treatment for one or more ciliopathies, in some embodiments being a subject that has, or is at risk of the one or more ciliopathies.
- the ciliopathy is selected from the group consisting of polycystic kidney disease, polycystic liver disease, retinitis pigmentosa, congenital fibrocystic diseases of the liver, diabetes, obesity, skeletal dysplasia's, Ahlstrom syndrome, Bardet-Biedl syndrome, Joubert syndrome, nephronophthisis, orofaciodigital syndrome 1, Senior-Loken syndrome, primary ciliary dyskinesia, Jeune asphyxiating thoracic dysplasia, Marden-Walker syndrome, situs inversus or isomerism, retinal degeneration, agenesis of the corpus callosum, anencephaly, cerebellar vermis hypoplasia, Dandy-Walker
- the dietary supplements and therapeutic compositions comprising ketonic agents may be utilized in methods of preventing or treating conditions such as cancer, a cystic condition of the liver, a pulmonary disease, autoimmune disease, a condition of the digestive tract, epilepsy, or infection.
- the dietary supplements and therapeutic compositions of the invention are used in the treatment of viral infection. It has been shown in the art that ketosis may increase the body's ability to fight viral infections, for example, as described in Goldberg et al., Ketogenic diet activates protective ⁇ T cell responses against influenza virus infection. Science Immunology, 2019; 4 (41): eaav2026.
- the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of preventing or treating viral infection.
- the scope of the invention encompasses a method of treating a viral infection, for example, preventing viral infection, in a subject by the administration to the subject of a therapeutically effective amount of a therapeutic composition comprising a ketonic composition.
- the viral infection may an infection caused by any pathogenic virus, for example influenza viruses, coronaviruses such as COVID19, HIV, noroviruses, respiratory syncytial viruses, herpes viruses, and papillomaviruses.
- a key signaling molecule activated in ADPKD is the kinase mammalian target of rapamycin (mTOR) that regulates many cellular behaviors including proliferation, cell growth, and energy metabolism and is responsive to growth factors, cellular energy status, and nutrient availability.
- mTOR inhibitors such as rapamycin, were highly effective in PKD rodent models but failed in subsequent clinical trials, most likely due to dose-limiting, significant extra-renal side effects and toxicities.
- dietary restriction strongly inhibits renal cyst growth due to metabolic changes caused by intermittent fasting.
- Time-restricted feeding in comparison to isocaloric ad libitum feeding, causes an intermittent decrease of blood glucose and an increase in ketogenesis and leads to strong inhibition of renal cyst growth, proliferation, and fibrosis.
- KD ketogenic diet
- Glucose Levels Predict the Rate of Kidney Volume Change in Individuals with ADPKD.
- Individuals with ADPKD and type 2 diabetes have significantly larger total kidney volume (TKV) than those with ADPKD alone, and overweight or obesity associates with faster progression in early-stage ADPKD.
- TKV total kidney volume
- serum glucose was explored in a cohort of human ADPKD subjects with preserved renal function. Baseline serum glucose in this cohort uniquely predicted a greater TKV and htTKV increase over time. Similar analyses found no effect of the baseline serum glucose on average yearly change in GFR. Together, these results suggest that glucose availability may directly affect renal cystic disease progression in ADPKD and that limiting glucose availability may ameliorate cystic progression in PKD.
- FIG. 2A total cyst number ( FIG. 2B ) and cyst size ( FIG. 2C ), were decreased in TRF animals compared to controls, demonstrating that TRF inhibited both cystogenesis and cyst expansion. Additionally, TRF-treated animals had increased levels of BHB and reduced blood glucose indicative of ketosis.
- TRF Reduces mTORC1 and STAT3 Signaling, Interstitial Fibrosis, and Proliferation in Cystic Kidneys. Changes in known PKD associated pathways and pathologies were assessed. A significant reduction in phosphorylated S6S 235/236 ( FIG. 3 ) a downstream target in the mTOR pathway, was observed in cyst-lining epithelial cells of TRF-treated male, but not female, Cy/+ animals indicating inhibition of mTORC1 activity. PKD is known to lead to interstitial fibrosis, a hallmark of progressive renal disease. Collagen deposition was markedly reduced in TRF compared to AL animals. Myofibroblasts were strongly reduced and frequently absent in kidneys of TRF animals.
- KD-treated rats exhibited decreased blood glucose and increased BHB levels compared to NC controls, and the level of ketosis was more profound than that achieved with the TRF regimen.
- Animals on the KD appeared phenotypically normal and did not exhibit any signs of distress during the study.
- KD-treated animals exhibited reduced body weight gain, and only gained approximately 2%-10% of their body weight each week during the study. This lack of growth was not dependent on caloric intake, as the KD group consumed comparable calories to NC controls relative to their body weight, likely resulting from protein restriction.
- KD had a disproportionate inhibitory effect on the growth of poly-cystic kidneys as compared to normal kidneys.
- KD feeding led to improved kidney function ( FIG. 4B ) as well as inhibited both cystogenesis ( FIG. 4C ) and cyst expansion ( FIG. 4D ).
- the KD again affected the organ size of polycystic kidneys disproportionally because wild-type kidneys or other organs, such as the heart, were largely unaffected.
- serum creatinine was unaffected by KD treatment in adult rats as was the total number of cysts per animal ( FIG. 6B ).
- cyst size FIG. 6C
- KD feeding prevents cyst growth in animals at that age.
- KD feeding led to a reduction in fibrosis in male animals, as indicated by reduced collagen, but there was no detectable difference in myo- fibroblasts, mTOR activity, or the cell cycle marker Ki-67.
- the fasting-induced modest decrease in body weight (12%) is expected due to depletion of fat and glycogen reserves, primarily in adipose tissue, liver, and skeletal muscle, respectively, and was consistent between wild-type and cystic animals. Strikingly, acute fasting strongly affected cystic kidneys, leading to a 20% reduction in cystic area ( FIG. 7C ) and a concurrent reduction in kidney mass and the 2-kidney/heart weight ratio. Fasting had minimal-to-no effect on the weight of hearts and normal kidneys as expected, indicating that the fasting effects are specific to PKD kidneys. The loss of mass was not due to any loss of glycogen, and the reduction of cystic volume accounted for the observed loss in kidney mass, demonstrating that acute fasting leads to a loss of cyst fluid.
- TUNEL staining revealed that acute fasting led to greater cell death of cystic cells but did not cause greater cell death in normal, non-cystic kidneys. In particular, there was a conspicuous number of TUNEL-positive, detached cells in cyst lumens, indicating that these dead cells originated from sloughed-off cyst-lining cells.
- Renal cysts in fasted animals frequently exhibited fragmented cells and denuded epithelium, which was not observed in renal cysts of control-fed cystic animals, demonstrating that loss of cyst fluid caused by acute fasting is due to cell death and disruption of the epithelial barrier of cysts, leading to draining of cyst fluid, presumably via the interstitium and lymphatics, leading to overall shrinking of polycystic kidneys.
- cystic cells intracellular oil droplets are rarely observed in normal or cystic kidneys in control-fed animals while acute fasting leads to accumulation of oil droplets in tubule cells in normal kidneys consistent with previous reports. Cyst-lining cells in polycystic kidneys exhibited a much exaggerated degree of cytoplasmic oil droplet accumulation. Frequently, most of the cytoplasm of the affected cells appeared to be occupied by oil droplets suggesting a state of severe steatosis. These findings demonstrate that cyst-lining cells have the ability to take up circulating fatty acids during acute fasting but are unable to sufficiently metabolize them, leading to lipotoxicity and greater cell death.
- BHB Treatment Prevents Polycystic Disease Progression in Juvenile Rats.
- Han: SPRD rats were treated with BHB from post-natal weeks 3-8 in the context of ad libitum feeding with normal, high-carbohydrate chow (NC).
- BHB was administered as a sodium and potassium salt in the drinking water ad libitum at a dose equivalent to that recommended as a dietary supplement in BHB supplement drinks.
- Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB supplement (a mixture of NaCl/KCl). All treated animals consumed comparable amounts of water and calories, and BHB treatment had no effect on body weight or blood glucose levels.
- BHB-treated PKD rats showed striking and unexpected reductions in the 2-kidney to body weight ratio and the cystic area ( FIG. 8A ) compared to water- and salt-treated controls. Neither wild-type kidneys nor other organs were affected by BHB treatment, indicating that the effect is specific to polycystic kidneys. Surprisingly, BHB treatment led to a strong reduction in fibrosis, almost complete elimination of myofibroblasts, improved kidney function (assessed by creatinine), and inhibition of proliferation.
- ketosis strongly inhibits not only renal cyst growth but also fibrosis.
- cyst proliferation and fibrosis typically go hand in hand, and it is possible that both processes may reinforce each other.
- Myofibroblasts have been shown to be abundant in PKD kidneys and are thought to be a major contributor to fibrosis.
- ketosis greatly and unexpectedly reduces the abundance of pericystic myofibroblasts, especially the TRF regimen and BHB treatment, to almost complete absence. Consequently, overall fibrosis, as measured by collagen deposition, is strongly reduced.
- BHB citrate
- citrate citrate
- PKD progression Han:SPRD rats were treated with BHB or a combination of BHB and citrate from post-natal weeks 3-8 in the context of ad libitum feeding with normal, high-carbohydrate chow (NC).
- BHB was administered as a sodium and potassium salt in the drinking water ad libitum at a dose equivalent to that recommended as a dietary supplement in BHB supplement drinks.
- citrate citrate was administered as a combination of tripotassium citrate and citric acid at a (0.82/1) ratio at a dose equivalent to that recommended utilized in citrate dietary supplements.
- Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB or BHB-citrate supplements (a mixture of NaCl/KCl). Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB or BHB-citrate supplements (a mixture of NaCl/KCl). All treated animals consumed comparable amounts of water and calories, and BHB treatment had no effect on body weight or blood glucose levels. After 5 weeks of treatment with BHB or BHB citrate, the kidneys of PKD animals were nearly indistinguishable from kidneys of wild-type animals both at the gross and histological level.
- BHB or BHB-citrate treated PKD rats showed striking reductions in the 2-kidney to body weight ratio ( FIG. 8A ) and the cystic area ( FIG. 8B ) compared to water- and salt-treated controls. Neither wild-type kidneys nor other organs were affected by BHB treatment, indicating that the effect is specific to polycystic kidneys.
- GPR109A Activation in PKD.
- the results described above led to the unexpected conclusion that BHB has a strikingly strong dominant inhibitory effect on PKD progression.
- the most immediate and likely assumption would be that BHB may act by virtue of its property as a metabolite that is taken up by cells and used for energy generation.
- GPR109A is a member of the class of G-protein coupled receptors.
- GPR109A is not only activated by niacin but also by high concentrations of BHB such as may occur during fasting-induced ketosis.
- BHB concentrations of BHB
- GPR109A knockout mice were crossed with a PKD model. In these mice, the loss of GPR109A surprisingly indeed led to accelerated PKD progression, indicating that GPR109A is normally a suppressor if cyst growth.
- PKD progression was ameliorated by niacin treated PKD mice (10 mg/kg, daily ip, from postnatal day 8-21) that express GPR109A (Genotype 1), while niacin treatment had no beneficial effect on PKD progression in the GPR109A knockout mice (Genotype 2).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 16/819,079, entitled “Methods and Compositions for Supporting Renal Health,” filed Mar. 14, 2020, which claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62/818,538 entitled “BHB and BHB-Citrate Combination Therapy for Polycystic Kidney Disease,” filed Mar. 14, 2019 the contents of which applications are hereby incorporated by reference.
- This invention was made with government support under grant number R01-DK109563 awarded by the National Institutes of Health. The government has certain rights in the invention.
- Renal disease is a major health issue. Among the various renal conditions that afflict people, renal cysts are present in numerous pathologies of the kidney. Polycystic kidney disease (PKD) is an especially serious condition with high morbidity and mortality. Autosomal dominant polycystic kidney disease (ADPKD) is considered the most common life-threatening monogenic disease. The PKD disease state is characterized by the growth of fluid-filled cysts in the kidneys which progressively enlarge, leading to destruction of normal renal tissue and function. Renal cyst growth in PKD is driven by several growth factors, hormones and cytokines that are present in the cyst fluid and which stimulate the cyst-lining epithelial cells. In the United States, the only FDA-approved therapeutic for ADPKD is the
vasopressin receptor 2 antagonist tolvaptan. Its use is complicated due to significant side effects and potential toxicities, poor cost-effectiveness and questions potentially limited efficacy. Accordingly, there remains a need in the art for effective ways of preventing and treating renal conditions, including cystic renal conditions such as polycystic kidney disease. - Polycystic kidney disease is one of several pathological conditions classified as a ciliopathy. Cilia are microtubule-containing structures that protrude from the surface of most cells types. Cilia, especially immotile primary cilia, act as a “cellular antenna” with various functions including sensory and cell-to-cell communication roles. Many pathological conditions are associated with mutations that result in abnormal cilial formation or function. There are over 35 known ciliopathies, and for many of these conditions, effective treatments are not available. Accordingly, there remains a need in the art for novel ways of preventing and ameliorating ciliopathies.
- Meanwhile, the metabolic state of ketosis is a growing area of study. Ketosis is characterized by elevated abundance of ketone bodies in blood and other compartments. Ketosis is a metabolic pathway induced by low glucose conditions, for example, being induced by low-carbohydrate diet or fasting. Numerous health benefits appear to be associated with dietary ketosis, including weight loss and appetite control, improved cholesterol status, and stabilization of blood glucose and insulin. The use of ketogenic diets has been applied to control epilepsy in children and blood glucose in
Type 2 diabetics. It is thought that ketogenic diets may be of benefit in addressing many other conditions, for example, in the context of kidney injury in surgical subjects, caloric restriction was found to have protective effect on renal function, as described in Grundmann et al., Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial. J Am Heart Assoc 7, (2018.) However, the mechanisms by which ketosis acts on pathological processes and conditions is not well understood, and previously recognized dietary benefits have not been translated to practical applications and interventions. Accordingly, there is a need in the art for an improved understanding of the molecular signaling mechanisms or other physiological effects by which ketosis achieves health benefits. Furthermore, long-term adherence to ketogenic diets is difficult and compliance is poor for many, if not most, subjects. Accordingly, there is further need in the art for novel therapies that harness the beneficial effects of ketosis while being readily administered or applied. - By various novel discoveries, the inventors of the present disclosure have provided the art with novel compositions of matter and methods for improving health and preventing and treating disease. The inventors of the present disclosure have elucidated that beta hydroxybutyrate (BHB), produced in dietary ketosis, activates certain beneficial pathways and processes. Among these, the activation of GPR109A by BHB is shown herein to provide various therapeutic effects. Based on these discoveries, the inventors of the present disclosure have identified and developed compositions with beneficial and therapeutic properties, and methods of applying them.
- In a first aspect, the scope of the invention encompasses novel compositions for promoting health, preventing disease, and treating pathological conditions. These compositions, termed “ketonic compositions” herein, comprise BHB, BHB precursors that convert to BHB in vivo, BHB-like molecules, and functional mimics of BHB, including chemically unrelated species, that recapitulate the beneficial signaling activities of BHB.
- Advantageously, the ketonic compositions can be formulated as dietary supplements, for convenient oral administration. In many cases, the ketonic compositions comprise inexpensive off-the-shelf ingredients with long-established safety profiles, and thus can be provided without the need for clinical trials, and may be utilized without the need for a prescription.
- In another aspect, by the discoveries herein, the scope of the invention encompasses novel uses of GPR109A agonists. Many such agents have been previously developed and clinically investigated for other purposes, and may be repurposed in the methods of the invention for novel therapeutic applications.
- In another aspect, the scope of the invention encompasses novel compositions and methods for improving renal health, and preventing and treating various conditions of the kidney. In one aspect, the inventions disclosed herein are advantageously applied for subjects at risk of or suffering from various renal cystic conditions, especially polycystic kidney disease. The scope of the invention encompasses dietary supplements and uses thereof for promoting renal health by preventing the formation of cysts and selectively destroying cyst epithelial cells.
- Likewise, in another novel use, ketonic agents may be used to prevent or ameliorate the severity of acute kidney injury, for example, being used as preventative agents prior to surgery to reduce the risk or severity of acute kidney injury associated with surgery. In another novel use, ketonic agents may be used to ameliorate the risk or severity of ischemic perfusion injury, for example, as preventative, e.g., presurgical treatments.
- In another aspect, the inventors of the present disclosure have determined that the ketonic agents of the invention may be combined with crystal precipitation inhibitors with synergistic beneficial activity. By preventing the formation of calcium, oxalate, or uric acid crystals, which underlie or exacerbate the pathology of various renal conditions such as cysts, acute kidney injury, and reperfusion injury, the combination products of the invention provide enhanced preventative and therapeutic effects. Specifically, citrate, a safe and readily available ingredient, is a crystal precipitation inhibitor that can be combined with ketonic agents, for example, in dietary supplements.
- In another aspect, the inventors of the present disclosure have developed novel compositions of matter comprising bi-functional molecules made up of a ketonic agent and a crystal precipitation inhibitor, for example, a BHB-citrate combined molecule. These novel combination products provide the art with synergistic beneficial effects from a single agent having favorable formulation and administration properties.
- In another aspect, the inventors of the present disclosure have determined that cystic epithelial cells are metabolically inflexible, being dependent upon glucose and being unable to metabolize fatty acids. Accordingly, in one aspect, the scope of the invention encompasses novel combination products made up of ketonic agents in combination with compositions that are lipotoxic to pathological cells such as polycystic kidney cyst epithelial cells and other undesirable cell types. The co-administration of ketonic agents and lipotoxic compositions provides enhanced preventatives and treatments for PKD cysts and other conditions.
- In another aspect, the scope of the invention encompasses novel means of preventing and treating ciliopathies. The ketonic compositions of the invention, including exogenous ketones and GPR109A agonists, may be utilized in dietary supplements and therapeutic compositions for ameliorating the risk, onset, and severity of numerous ciliopathies such as PKD and retinitis pigmentosa.
- These various inventions, and other beneficial applications of the discoveries disclosed herein, address a number of unmet needs in the art, as described in more detail in the sections that follow.
-
FIG. 1 is a diagrammatic representation of the effects of a ketogenic diet or the application of ketonic compositions on polycystic kidneys. Without intervention, kidneys are ridden with cysts and cysts expand (left). With sufficient intervention, cysts are reduced and kidneys return towards normal condition (right). -
FIGS. 2A, 2B, and 2C depict the effects of time-restricted feeding in a PKD rat model.FIG. 2A depicts the cystic index (percent cystic area) for kidneys of rats on the TRF or AL diet.FIG. 2B depicts the total number of cysts per kidney section in AL and TRF animals.FIG. 2C depicts cyst sizes of the cysts counted in 2B. -
FIG. 3 depicts the abundance of pS6-positive cells in cyst-lining epithelia as a percent of the total number of DAPI-stained nuclei PKD rats on AL diet TRF diet. -
FIGS. 4A, 4B, 4C, 4D, and 4E depict the effects of a ketogenic diet on disease progression in juvenile Han:SPRD rats.FIG. 4A depicts the cystic index (percent cystic area) from NC (normal chow) and KD (keto diet) cystic rats. [Dr6]FIG. 4B depicts serum creatinine.FIG. 4C depicts total number of cysts per kidney section.FIG. 4D depicts the size of cysts counted inFIG. 4C .FIG. 4E depicts quantification of pS6-positive cells in cyst-lining epithelia as a percent of the total number of DAPI-stained nuclei in cysts. Error bars represent SD. Statistical significance determined from Mann-Whitney analysis. n=8 male and 7 female Cy+ rats; n=13 male and 6 female wild-type rats for ketogenic diet experiments (*p<0.05, ****p<0.0001). -
FIGS. 5A, 5B, and 5C depict PKD progression in rats treated with keto diet.FIG. 5A depicts Cystic index (percent cystic area).FIG. 5B depicts the total number of cysts per kidney section.FIG. 5C depicts the size of cysts counted inFIG. 5B . -
FIGS. 6A, 6B, and 6C depict effects of fasting (acute 48-h fast) in Han:SPRD and WT rats.FIG. 6A depicts blood BHB levels in male rats.FIG. 6B depicts blood BHB levels in female rats.FIG. 6C depicts cystic index (percent cystic area) in kidneys of fasted PKD rats. -
FIG. 7 depicts the cystic index (percent cystic area) in Han:SPRD PKD rats administered BHB, vs. control rats given water or water with salt equivalent to the BHB treatment. -
FIGS. 8A and 8B depict the effects of varying concentrations of BHB and citrate, as well as BHB-citrate combination treatments, in PKD rats.FIG. 8A depicts 2-kidney to total body weight ratio in wild type (WT) and Cy+ PKD rats.FIG. 8B depicts cystic area (percent cystic area) in kidneys of the treated PKD rats. -
FIG. 9 depicts PKD progression (as assessed by 2-kidney to total body weight ratio) in niacin-treated PKD mice that express GPR109A (Genotype 1), and in GPR109A knockout PKD mice (Genotype 2). - The various inventions disclosed herein are directed to dietary supplements, pharmaceutical compositions, and other compositions comprising BHB or BHB-related compounds, and the novel uses of such compositions in maintaining health, preventing disease and treating various conditions. In a primary embodiment, the support of kidney health and the treatment of kidney disease is encompassed by the compositions and methods of the invention, for example, the treatment of polycystic kidney disease.
-
Part 1. Compositions of the Invention - In a first aspect, the scope of the invention encompasses compositions which may be used to promote wellness, prevent disease, or treat various conditions. The compositions of the invention encompass BHB and other ketone bodies and variants thereof as well as unrelated chemical structures which functionally recapitulate the biological and therapeutic effects of BHB. Therefore, the compositions of the invention will be referred to herein broadly as “ketonic compositions.” As set forth below, the ketonic compositions of the invention may comprise any number of ketone bodies, ketone body precursors, ketone body functional mimics, and multifunctional combination products comprising two or more ketone bodies or analogs. In some implementations, the scope of the invention encompasses multifunctional combination products comprising ketone bodies or analogs with additional functional agents that augment or synergize the benefits of the ketones. In some embodiments, the ketonic compositions of the invention comprise novel compositions of matter. In some embodiments, the ketonic compositions of the invention comprise known compositions of matter that are repurposed for novel uses.
- Ketosis Mimic. In a first aspect, the ketonic composition of the invention encompasses a ketosis mimic. As used herein, a ketosis mimic is a composition of matter which, when administered to a subject, induces or recapitulates, in whole or in part, processes or states active in ketosis, for example, dietary ketosis, i.e. ketosis induced by fasting or otherwise restricting glucose, for example, a blood ketone level of 0.5mM or greater.
- In one aspect, the ketosis mimic may comprise an exogenous ketone. An exogenous ketone is an exogenously applied ketone body that is structurally or functionally like BHB or other ketone bodies found circulating in subjects experiencing ketosis, e.g. dietary ketosis, or which is converted to a ketone body in vivo.
- BHB and BHB Analogs. In a primary implementation, the ketosis mimic is BHB or a BHB analog. As known in the art, beta-hydroxybutyric acid, abbreviated BHB, is a ketone that is synthesized in the liver from acetyl-CoA formed from the breakdown of fatty acids via several intermediates and reaction steps. BHB is formed in ketosis or other low glucose conditions. STRUCTURE 1:
- For example, BHB may be employed either as the free acid or as a salt or a mixture of both. BHB or BHB salts are preferentially administered in oral formulations for gastrointestinal absorption leading to distribution via the circulation and effects of BHB in the body including the kidneys.
- Likewise, analogs of BHB may also be employed in the compositions and methods of the invention. Direct administration BHB in its free acid form may be problematic due to its acidity. Likewise, administration of BHB salts may be problematic due to increased salt intake which may be undesired. Accordingly, in various implementations, a composition that is converted to BHB in vivo or which mimics BHB may be used in place of free BHB or BHB salts. As used herein, “BHB analogs” broadly encompasses compositions that (1) are converted to BHB in vivo or (2) have structural similarly to BHB and promote like physiological responses as those promoted by BHB.
- In one embodiment, the BHB analog is a precursor of BHB. A BHB precursor is a composition that is converted to BHB in vivo via one or more reactions or intermediates. In one embodiment, the BHB precursor is butyrate. In one embodiment, the BHB precursor is beta-hydroxy beta-methylbutyrate. In one embodiment, the BHB precursor is a ketogenic amino acid or a deaminated keto-analogue of a ketogenic amino acid. In one embodiment, the BHB precursor is acetoacetate (the physiological form of acetoacetic acid). In one embodiment, the BHB precursor is poly-beta-hydroxybutyrate. In one embodiment, the BHB precursor is beta-hydroxybutyryloxy-butyrate.
- In one embodiment, the BHB precursor is 1,3 butanediol, Structure 2:
- 1,3 butanediol is water soluble and well tolerated by animals, including humans. In the body, it is efficiently converted to BHB by enzymatic and/or chemical action, for example, wherein alcohol dehydrogenase catalyzes metabolism of 1,3-butanediol to beta-hydroxybutyraldehyde, which is subsequently oxidized to beta-hydroxybutyrate by aldehyde dehydrogenase. Advantageously, 1,3 butane diol is neutral and can be administered directly without the need to formulate as a salt. In one embodiment, the BHB precursor is 1,3-butanediol diacetoacetate. 1,3-butanediol diacetoacetate is water soluble, well tolerated in animals and converted to BHB in vivo.
- In one embodiment, the BHB analog comprises a BHB precursor comprising a fat molecule which is readily converted to ketones in the body. In one embodiment, the BHB precursor is a medium chain triglyceride (MCT), for example, a triglyceride comprising six to 12 carbon chains. MCTs are more efficiently converted to ketones in vivo than shorter or longer chain fats. Exemplary MCTs include caproic acid (C6), caprylic acid (C8), capric acid (C10), and lauric acid (C12).
- BHB Esters. The BHB analogs of the invention further encompass esters of BHB, and esters of BHB analogs, wherein the oxygen of the hydroxyl group of the BHB carboxylic acid moiety (carbon 1) is conjugated with a hydroxyl group of another compound. Exemplary esters include methyl, ethyl, propyl (e.g. n-propyl or 2-propyl), butyl (e.g. tert-butyl), pentyl, hydroxylbutyl, hydroxylpropyl, glycerol, citrate, or glycol groups joined to the 1 carbon of BHB. Other exemplary esters are 3-hydroxybutyrate-(R)-1,3-butanediol monoester. Esters of BHB at the 1 carbon eliminate the carboxylic acid group and associated charge. In vivo, these compositions are de-esterified by esterase enzymes, releasing BHB (or the BHB analog or mimic in some cases). Such compositions may have improved solubility, increased membrane permeability, improved stability, more sustained release, and increased tolerance compared to native BHB or BHB analogs. Reference to “BHB” and “BHB analogs” herein will be understood to encompass esters of BHB and esters of BHB precursors and mimic compositions. Esters of the 3 carbon are also within the scope of the invention.
- Various BHB esters are known in the art. Additional BHB esters may include compositions of the formula:
STRUCTURE 3 - wherein R1 and/or R2 may be an alkyl moiety, for example, comprising one to twelve carbons, for example, methyl, ethyl, propyl (e.g. n-propyl or 2-propyl), butyl (e.g. tert-butyl), pentyl, hydroxylbutyl, hydroxylpropyl, glycerol, citrate, or glycol.
- In some embodiments the BHB analog is a polymer of BHB or a polymer of a BHB analog. One example is polymeric BHB which is a polymeric ester between the carboxyl group of BHB and the hydroxyl group of BHB. Hydrolysis of polymeric BHB, for example in the gastrointestinal tract, either chemically, enzymatically or mediated by microorganisms, may lead to release of monomeric BHB and uptake into circulation.
- In some embodiments, the therapeutic composition of the invention comprises a BHB prodrug, or BHB analog prodrug. A BHB prodrug, or BHB analog prodrug, is a composition comprising a cleavable promoiety conjugated to BHB, or a BHB analog. In the body of a subject to which the prodrug is administered, the promoiety is cleaved by enzymatic or chemical action to release the BHB, or BHB analog. In a primary embodiment, the promoiety is joined to the BHB or BHB analog by ester linkage to the 1 and/or 3 carbon.
- Various BHB analogs, including BHB esters and oligomers, are known in the art. Any such compositions may be selected as the ketonic composition of the invention. In one embodiment, the BHB analog comprises 3-hydroxybutyl 3-hydroxybutyrate, as described in U.S. Pat. No. 10,051,880, Hydroxybutyrate ester and medical uses thereof, by Clarke and Veech. In one embodiment, the BHB analog comprises R,S-1,3-butanediol acetoacetate, for example, as described in U.S. Pat. No. 9,795,590, Ketone supplements for treatment of angelman syndrome, by Weeber et al. In one embodiment, the BHB analog is an oligomer of (R)-3 -hydroxybutyrate, for example, as described in U.S. Pat. No. 10,559,258, Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives, by Veech and King. The BHB analog may comprise a composition described in U.S. Pat. No. 10,376,528, Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor, by Schmidt or in U.S. Pat. No. 5,693,850, Nutritive water soluble glycerol esters of hydroxy butyric acid, by Birkhahn et al..
- Enantiomers. BHB is a chiral composition having two enantiomers: D-β-hydroxybutyric acid (also known as R-β-hydroxybutyric acid) and L-β-hydroxybutyric acid (also known as S-β-hydroxybutyric acid). The D- and L-forms of BHB are determined by the tetrahedral orientation of the hydroxyl group (or oxy group, in BHB esters) on the third carbon of BHB. D-BHB is the most common endogenous form of BHB. L-BHB is only occurring in small amounts in cells, and thus is metabolized or cleared at a slower rate, while retaining key signaling properties of endogenous D-BHB.
- Reference to “BHB” or a “BHB analog” made herein will be understood to encompass any mixture of D-BHB and L-BHB isoforms, unless the proportion of the enantiomers is specifically specified. Exemplary mixtures of enantiomers include substantially pure formulations of D-BHB and D-BHB analogs, for example, formulations comprising at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% D-BHB or a D-BHB analog. Likewise, the mixture of enantiomers may comprise a substantially pure formulation of L-BHB or a L-BHB analog, for example, formulations comprising at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% L-BHB or L-BHB analog. In other embodiments, the percentage of D-BHB or D-BHB analog in the mixture may be at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% (racemic mixture), 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- GPR109A Activators. In one aspect, the ketonic compositions of the invention will comprise an activator of GPR109A. GPR109A, also known as hydroxycarboxylic acid receptor 2 (HCA2), and niacin receptor 1 (NIACR1 in humans) is a hydroxycarboxylic acid receptor. In humans, GPR109A is encoded by the HCAR2 gene. As used herein, a GPR109A agonist or activator is a composition which activates, i.e. increases the activity of, GPR109A. In one embodiment, GPR109A activation is indicated by a reduction in intracellular cAMP concentration. In one embodiment, GPR109A activation is indicated by a reduction in lipolysis. Activation of GPR109a occurs when a ligand or agonist binds to this receptor and causes a conformational change that then leads to activation of an associated heterotrimeric G-protein, in this case typically a Gi/G0-type G protein. The activated G protein then regulates subsequent intracellular signaling pathways such as the inhibition of adenylate cyclase leading to lowering of the intracellular cAMP concentration. Both, natural ligands—such as BHB—and artificial ligands—such as certain pharmacological compounds—can act as agonists of GPR109A.
- In one embodiment, the GPR109A agonist is an exogenous ketone. The inventors of the present disclosure have unexpectedly determined that ketones present in ketosis have GPR109A activation activity and that this activity underlies various beneficial processes and effects of dietary ketosis. In one embodiment, the exogenous ketone is BHB or BHB analog, as described above.
- In alternative implementations, the GPR109A agonist is a non-ketone. In one embodiment, the GPR109 agonist is niacin, or a niacin analog such as inositol nicotinate. It will be understood that niacin in small doses is not sufficient to significantly activate GPR109A, and that dosage forms of less than the minimal dose, or doses administered at less than the minimal activation dose will not be considered GPR109A activators. In one embodiment, the niacin or niacin mimic is provided (e.g. a dosage form) or administered in a biologically or therapeutically effective amount, being an amount sufficient to significantly activate GPR109A, for example, in various embodiments being at least 100 mg, 250 mg, at least 500 mg, at least 750 mg, at least 1 gram, or at least 1.5 gram, for example, in human subjects. In some embodiments, niacin provided or administered in a biologically or therapeutically effective amount comprising a megadose suitable for activation of GPR109A, for example, a dosage form or a daily administration of, for example 1 to 6 grams daily.
- In various embodiments, the GPR109A agonist may be any of the following, as well as variants, derivatives, and polymorphs of the following. In one embodiment, the GPR109A agonist is GSK256073, for example, as described in Specher et al., 2015, Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist, Eur J Pharmacol 756: 1-7. In one embodiment, the GPR109A agonist is selected from the group consisting of (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903), monomethylfumarate acipimox, acifran, 3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4- carboxylic acid pyrazine-2-carboxylic acid, LUF6281 and LUF6283, and a pyrazolyl propionyl cyclohexenamide, for example, as described in Ding et al., 2010, Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A, Bioorg Med Chem Letters 21: 2721-2724; Palani et al., Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia, ACS Med Chem Lett. 2012 3(1): 63-68. Additional GPR109 agonists include compositions described in PCT International Patent Application Publication Number WO2008051403, Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A, by Beresis and Colletti; U.S. Pat. No. 7,723,342, Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia, by Palani et al.; United States Patent Application Publication Number US20090062269, Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment, by Raghavan et al.
- In one embodiment, the GPR109A agonist is 5-[3-(1-methylcyclopropyl)propyl]-1H,2H,3H,4H,7H-pyrano[2,3-d]pyrimidine-2,4,7-trione, also known as SCH900271, a nicotinic acid derivative known in the art for the treatment of dislipideima. In one embodiment, the GPRO19 agonist is (4aR,5aR)-4,4a,5,5a-Tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2]pyrazole-3-carboxylic acid, also known as MK1903.
- The present disclosure makes reference to the administration or ingestion of “a ketonic composition.” It will be understood that reference to a ketonic composition encompasses “one or more” ketonic agents, for example, one ketonic agent or a combinations of two or more difference ketonic agents. Combinations of different ketonic agents may be utilized, for example having different ADMET properties or physiological effects, in order to optimize the delivery, distribution, and action of ingested or administered products or to broaden the therapeutic effects thereof.
- Synergistic Combination Products. The inventors of the present disclosure have advantageously determined that the efficacy of ketonic compositions such as BHB, BHB analogs, and GPR109A agonists is dramatically, and synergistically, enhanced when the agent is combined with a crystal precipitation inhibiting agent. The crystal precipitation inhibiting agent, as used herein, encompasses any agent that acts to inhibit the in vivo formation of crystals such as calcium or uric acid crystals. As is discussed below, in various contexts, crystal formation may be pathological or may promote pathological outcomes, for example, in the kidney. By inhibiting undesirable crystal precipitation, administration of the crystal precipitation-modulating compositions of the invention enhances the therapeutic effects of ketonic compositions such as BHB, BHB analogs, and GPR109A activators. In one aspect, the scope of the invention encompasses a novel combination product comprising a ketonic composition and a crystal precipitation inhibitor, e.g. BHB or a BHB analog (such as a BHB precursor) in combination with the crystal precipitation inhibitor. In a related embodiment, the scope of the invention encompasses methods of supporting health, e.g. renal health, or treating an enumerated condition (e.g. a renal or cystic condition, e.g., PKD) by the administration of a biologically or therapeutically effective amount of the combination product.
- The crystal precipitation inhibitor composition may comprise any agent that inhibits the formation of crystals in physiological contexts, for example, the formation of calcium oxalate crystals, the formation of calcium phosphate crystals, and the formation of uric acid crystals. In one embodiment, the crystal precipitation inhibitor is a calcium chelator. In some embodiments, the crystal precipitation inhibitor composition is a buffering agent or pH-modulating agent that changes pH to inhibit crystal precipitation, for example, a pH-raising agent which inhibits uric acid crystal formation.
- In a primary embodiment, the crystal precipitation-modulating composition is citrate. Citrate, as referred to herein, encompasses citric acid itself, or salts and esters of citric acid. For example, citrate may comprise a mono-, di- or tri-valent salt of citrate with sodium, potassium, magnesium, calcium, other cations, or mixtures of cations, or mixtures of citric acid with citrate salts. For example, citrate may comprise a mono-salt, for example a mono-sodium salt, for example, the sodium salt of STRUCTURE 4, or other salts wherein a different cation is used:
- In one aspect, the scope of the invention encompasses a novel combination product comprising a ketonic composition and citrate, e.g. BHB or a BHB analog (such as a BHB precursor) in combination with citrate. In a related embodiment, the scope of the invention encompasses methods of supporting health, e.g. renal health, or treating an enumerated condition (e.g. a renal or cystic condition, e.g., PKD) by the administration of a biologically or therapeutically effective amount of the combination product comprising BHB or a BHB analog an citrate. Citrate may be administered as a salt of magnesium, potassium, calcium, sodium, or other forms. The use of citrate alone in the treatment of polycystic kidney disease in rats has been disclosed, for example, by Tanner and Tanner, Dietary Citrate Treatment of Polycystic Kidney Disease in Rats Nephron Physiol 2003; 93:p14-p20 and in Tanner, Tanner, Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease, JASN July 1998, 9 (7) 1242-1248. However, the combination of BHB or other ketones and citrate has not been disclosed.
- In some embodiments, the crystal precipitation-modulating composition is a citrate analog, for example, a composition having structural similarity to citrate and retaining the crystal precipitation-modulating properties of citrate. Exemplary citrate analogs include derivatives of citric acid known in the art. Exemplary citrate analogs include esters of citric acid (e.g. monoester, diester, triester), amides of citric acid, 1,3 dioxal-4-ones, sidophores, peroxycitric acid, hydroxycitrate, and tricarballylic acid. Exemplary citrate analogs include compositions described in Milewska, 1988, Citric Acid, its natural and synthetic derivatives, Z Chem 28: 204-211.
- In some embodiments, the crystal precipitation inhibitor is a composition that alkanizes urine, such as a carbonate or bicarbonate composition, such as magnesium carbonate or bicarbonate, calcium carbonate or bicarbonate, or sodium carbonate or bicarbonate. In some embodiments, the crystal precipitation-modulating composition is a compound that can decrease the level of uric acid in the urine and may be used to treat hyperuricemia. Such compounds will decrease the risk of formation or uric acid crystals. Three examples are allopurinol, oxypurinol and febuxostat, inhibitors of xanthine oxidase, that act on purine catabolism, reducing the production of uric acid. Another example is Lesinurad which inhibits the function of transporter proteins involved in renal uric acid reabsorption (uric acid transporter 1 [URAT1] and organic anion transporter 4 [OAT4]), and lowers serum uric acid levels. Another example is Rasburicase, a recombinant urate-oxidase enzyme, which converts uric acid to allantoin (an inactive and soluble metabolite of uric acid).
- In various implementations, the therapeutic compositions of the invention comprise a combination of a ketonic composition, e.g., one or more of BHB, a BHB analog, and/or a GPR109A activator, in combination with one or more crystal precipitation-modulating compositions, for example, a combination of BHB and citrate, for example an admixture of the two in a capsule, tablet, powder, beverage, or edible item By formulating the therapeutic compositions of the invention as combination products, the recipient may advantageously be administered a single agent with dual, synergistic therapeutic properties.
- In an alternative implementation, the combination product is provided with the ketonic composition and crystal precipitation inhibitor as two separate dosage forms, optionally packaged in a single package. For example, two separate tablets, capsules, powders, e.g. a BHB capsule and a citrate capsule, may be provided with instructions to take them at the same time. By formulating the therapeutic compositions of the invention as individual entities, the recipient may benefit from the synergistic therapeutic properties but advantageously has the option to modify the individual doses according to specific needs.
- It will be understood that citrate is a common additive to dietary supplements and other food items. For example, sodium citrate or potassium citrate are known additives used as flavoring agents, preservatives, and pH buffers. The quantity of citrate used for such purposes is therapeutically insignificant. The scope of the invention encompasses synergistic combination products comprising citrate wherein the quantity of citrate is biologically effective, i.e. sufficient to inhibit crystal precipitation in vivo, for example, crystal precipitation in the kidney. For example, when citrate is configured for oral administration, the biologically effective dosage may be in the range of 100 mg to 10 grams citrate per day. In various embodiments, the citrate dose is about or at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 mg citrate or citrate salt per dose, per dosage form, or cumulative dosing per day. In an alternative method of assessing citrate dose, the dose may be in the range of 0.1 mmol- 10 mmol citrate/100 g body weight per dosage, or per day, for example, a dosage of about or at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2. 2.3, 2.4, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10 mmol citrate/100 g body weight per dose, or cumulative dose per day. In another method of dosage calculation, the citrate dosage is in the range of 0.1 to 10 mg citrate or citrate salt per m2 body area per dosage or per day, for example at being about or at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5., 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 or 10 mg per m2 body area.
- In some implementations, the biologically effective citrate is defined in terms of its abundance relative to the co-administered ketonic agent, e.g. BHB or a BHB analog. For example, in various embodiments, the ratio of citrate molecules, or mass of citrate, to BHB or BHB analog molecules (or mass) is in the range of 1:10 to 10:1. Exemplary ratios of citrate to BHB or BHB analog (by molecule or by mass) are in the range of 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.
- In some implementations, the amount of citrate in the combination product is described in terms of the weight percentage of citrate in the combination product. In one embodiment, the weight percentage of citrate is calculated as proportional mass of citrate to the mass of citrate and the one or more ketonic compositions (e.g. the weight percentage of citrate with respect to active ingredients only). With respect to this measure, the weight percentage of citrate may be in the range of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%. In one embodiment, the weight percentage of citrate is calculated as the proportional mass of citrate to the mass of the entire formulation, including citrate, ketonic compositions, and carriers and other inert ingredients (e.g. the weight percentage of citrate with respect to the entire product). With respect to this measure, the weight percentage of citrate may be in the range of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%.
- Bi-Functional Molecules. In one embodiment, the scope of the invention encompasses novel compositions, advantageously comprising a bi-functional molecule comprising one or more ketonic compositions, e.g. one or more of BHB, a BHB analog, or a GPR109A agonist, conjugated to one or more molecules of a crystal precipitation-modulating agent. In various embodiments, the dietary supplements and therapeutic compositions of the invention comprise such compositions. The use of such compositions advantageously provides a ketosis mimic and/or GPR109A agonist in combination with a crystal precipitation inhibitor in a single composition, at a desirable stoichiometric ratio. Additionally, the bi-functional molecules may be designed to be neutral or less acidic, thereby avoiding or reducing the need for salt formulation.
- In one embodiment, the bi-functional molecule comprises a BHB-citrate ester, comprising one or more BHB molecules and/or one or more a BHB analog molecules conjugated to citrate. Exemplary BHB-citrate esters include STRUCTURE 5:
- wherein R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is ketonic composition. In one embodiment, R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is BHB. In one embodiment, R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is a BHB analog. In one embodiment, R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is 1,3 butanediol. In one embodiment, R1, R2, or R3 may be hydrogen, alkyl, or another composition, and at least one of R1, R2, and R3 is a GPR109A activator.
- Exemplary bi-functional molecules include Structure 6:
- Structure 7:
- and
- Structure 8:
- Synthesis of bi-functional molecules. The bi-functional BHB-citrate esters and like composition of the invention may be synthesized according to known methods for the esterification of citrate and like molecules. For example Fischer-Speier esterification may be employed by refluxing citric acid with an excess of 1,3-butanediol in the presence of an acid catalyst such as sulfuric acid. Such a reaction is expected to yield a mixture of
structures - Combination Product Comprising Lipotoxic Compositions. Due to the metabolic inflexibility of epithelial cells in cysts, such as PKD cysts, for example, ADPKD cysts, in some implementations, the compositions and methods of the invention encompasses a combination product comprising a ketonic composition, e.g., one or more of BHB, a BHB analog, and/or a GPR109A activator, and a lipotoxic agent. The lipotoxic agent may comprise any fatty acid or other composition which create toxicity for cells that are dependent upon glucose for energy production and may be defective in beta-oxidation of fatty acids, i.e. having enhanced sensitivity to lipotoxicity from lipids that accumulate but which cannot be metabolized. Exemplary glucose dependent cells include cyst epithelial cells, including PKD cyst epithelial cells and liver cyst epithelial cells, and cancer cells.
- In one embodiment, the lipotoxic composition is an MCT, as described above. Exemplary MCTs include triglycerides comprising six to 12-carbon chains, including caproic acid, caprylic acid, capric acid, and lauric acid.
- Additionally, unsaturated fatty acids may act as lipotoxic agents for glucose-dependent cells. Exemplary unsaturated fatty acids include monounsaturated and polyunsaturated fats such as a-Linolenic acid, Stearidonic acid, Linoleic acid, Linolelaidic acid, γ-Linolenic acid, Palmitoleic acid, Vaccenic acid, Oleic acid. Such unsaturated fatty acids may be administered alone or in mixtures as free fatty acids or their salts or as triglycerides. Alternatively, these unsaturated fatty acids may be administered in the form of natural fats and oils that are rich in these unsaturated fatty acids, for example including oils from flaxseed, walnuts, chia, hemp, and other vegetable oils.
- The lipotoxic agents advantageously compositions that can be taken orally and which are used in various food products and supplements. In one embodiment, the lipotoxic agents are included in dietary supplements of the invention. The dosage of lipotoxic agents will be in the range of 0.5-100 g per day, for example about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 90 g per day. .
- In certain embodiments, the combination product comprising a ketonic composition and a lipotoxic composition further includes a crystal precipitation-modulating agent (e.g. citrate). For example, the combination product may comprise BHB (or a BHB analog) in combination with citrate (or a citrate analog) in combination with one or more lipotoxic compositions, representing a tri-functional agent.
- Formulations of the Ketonic Compositions and Combination Products. It will be understood that the ketonic compositions and combination products containing such described herein may be formulated in various ways for effective and controlled delivery. It will be understood that the compositions may comprise the active agents described herein in combination with any number of ingredients that facilitate effective ingestion, administration, delivery, adsorption, distribution, and metabolism of the active agents. In various embodiments, the compositions described herein comprise dietary supplements, or therapeutic compositions (including therapeutic compositions formulated as dietary supplements). Further, all compositions described herein containing or comprising ketonic agents may be considered “medicaments.” Furthermore, the act of manufacturing, including formulating, ketonic agents into dietary supplements, therapeutic compositions, or any ingested or otherwise administered compositions will be presumed to be performed under any specified processes therefor, and if no process is specified, then the act of manufacture, including formulation, will be assumed to be achieved by standard means known in the art. Thus recital of any described compositions wherein ketonic compositions are included, will be presumed to encompass an implied method of making such medicaments.
- In various embodiments, the ketonic composition (e.g. BHB, BHB analog, and/or GPR109A activator) is formulated as a salt. Pharmaceutical salt formulations are known in the art and may impart higher solubility, stability, and bioavailability to the therapeutic molecules. Exemplary salts include salts of amino acids, alkali metals, alkaline earth metals, transition metals, for example: arginine salts, calcium salts, chromium salts, citrulline salts, cobalt salts, copper salts, creatine salts, glutamine salts, histidine salts, iron salts, isoleucine salts, leucine salts, lithium salts, lysine salts, magnesium salts, manganese salts, molybdenum salts, ornithine salts, potassium salts, selenium salts, sodium salts, and zinc salts.
- In one primary implementation, the ketonic agents of the invention are formulated in a low-salt or zero-salt formulation, to avoid stressing the body, especially the kidneys, of the recipient. For example, a low-sodium and low-potassium and low-calcium formulation may comprise a formulation that would lead to an added sodium or potassium or calcium intake of no more than 500 mg/day each, preferably less.
- The ketonic compositions of the invention may be formulated for efficient delivery by a selected route. The ketonic compositions of the invention may be formulated in combination with pharmaceutically acceptable excipients, carriers, diluents, release formulations and other drug delivery or drug targeting vehicles, as known in the art.
- Advantageously, the ketonic compositions of the invention are amenable to efficient oral delivery and may be formulated therefor. Oral formulations may include any number of fillers, flavoring agents, coloring agents, sweeteners, and other compositions used in the art for oral delivery of agents. In one embodiment, the pharmaceutical composition is formulated for oral delivery in tablets or capsules. In one embodiment, the pharmaceutical composition is formulated as a powder to be mixed with liquid. In one embodiment, the ketonic composition is formulated as a liquid containing the therapeutic agent, i.e. solutions, such as water or other flavored drinks containing BHB or a BHB analog.
- In alternative implementations, the ketonic compositions of the invention are formulated for administration via non-oral routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal delivery. In one embodiment, the ketonic compositions of the invention may be formulated for microbubble delivery for example, ultrasound meditated microbubble delivery, for site-specific delivery. In one embodiment, the ketonic compositions comprises nanoparticles containing or functionalized with the selected active agent of the ketonic composition, for delivery by nanoparticle-based delivery methods. In one embodiment, the ketonic composition comprises the selected therapeutic agent admixed with a polymeric material for timed release elution of the agent or to prevent premature digestion of the material in the digestive tract. In one embodiment, the ketonic composition comprises chemically conjugated magnetizable particles or use in magnetic-directed drug delivery methods, as known in the art. In one embodiment, the ketonic composition of the invention is coated onto an implant or drug eluting device.
- In one embodiment, the therapeutic composition of the invention comprises a targeting moiety that facilitates delivery to a target cell type or organ, such as the kidneys, liver, cysts, or other sites. In one embodiment, the ketonic composition of the invention is conjugated to a polymeric immunoglobulin such as a polymeric IgM or IgA. Such agents may be efficiently targeted to renal cysts, for example, cysts present in the case of polycystic kidney disease.
- Administration. The various methods of the invention may encompass the administration of an agent to a subject. Administration, as used herein, may encompass the act of providing the agent to the subject or actually introducing the agent into the subject. Administration as used herein will encompass self-administration. For example, in a primary implementation of the methods of the invention, dietary supplements are ingested by a subject. Such ingestion will be considered administration, i.e., self-administration of the enumerated composition. Administration may also comprise provision of a selected composition to the subject, for example, providing food or liquids that contain the composition to an animal.
- Dietary Supplements. In a primary implementation of the methods of the invention, the ketonic composition is formulated and administered as a dietary supplement. A dietary supplement is a composition that is administered orally, for example, in food or drink, with food or drink, or which otherwise supplements the regular intake of food. From a regulatory standpoint, a dietary supplement is generally a composition that can be purchased and used without a prescription. For example, in the United States, per the Food and Drug Administration and The Dietary Supplement Health and Education Act of 1994, a dietary supplement is “a product intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any ingredient just described.”
- The dietary supplements of the invention may encompass any formulation for oral delivery. In a primary implementation, the ketonic compositions of the invention are ingested in liquids, for example, being formulated in any number of beverage formats, including infused water, sports drinks, energy drinks, teas, fruit juices, or meal replacement beverages. In one embodiment, the ketonic compositions of the invention are formulated as a powder which may be dissolved in water, or other drinks such as fruit juice, coffee, or tea. In some embodiments, the powder is packaged in individual packets or vials at a measured dose. In some embodiments, the powder is packaged with a scoop which measures the correct dose for mixing with liquid and instructions for doing so at a specified frequency.
- In an alternative dosage form, the dietary supplement of the invention is formulated as a capsule, tablet, or chewable tablet. In some implementations, the dietary supplements of the invention are ingested as a component of an edible item, for example, being incorporated into gummies, cookies, snack bars, meal replacement bars and other bars, cereals, biscuits, crackers, confectionery items, and probiotic formulations including yogurt, and other food items. In some cases the dietary supplements of the invention are formulated as products for non-human animals, such as chow, feed, treats or snacks, or supplemented pet food.
- In the case of combination products comprising a ketonic composition in combination with a secondary agent (e.g. a crystal precipitation inhibitor such as citrate or a lipotoxic agent such as unsaturated fatty acids), the dietary supplements are preferably formulated as a single product containing both the ketonic composition (e.g. BHB or BHB analog) and the secondary agent so that only a single product is required to be digested. However, it will be understood the scope of the invention includes separate formulations and dosage forms of the ketonic composition and secondary agents, to be ingested separately.
- Part 2: Methods of Use
- The scope of the invention encompasses numerous methods directed to the use of ketonic compositions for the maintenance of health, prevention of disease, and in therapeutic applications. In one aspect, the scope of the invention encompasses methods of using dietary supplements comprising ketonic compositions for supporting health. In another aspect, the scope of the invention encompasses the use of ketonic compositions in therapeutic methods for the prevention and treatment of various diseases and pathological conditions.
- The methods disclosed herein will be directed to the use of ketonic compositions by, and administration of ketonic compositions to, subjects. The subject may be a human subject, for example, in some contexts, a patient. The subject may comprise a non-human animal of any species, including test animals, veterinary subjects, pets, and livestock, for example, any of mice, rats, dogs, cats, sheep, goats, cows, pigs, horses, camels, non-human primates, or other animals. For example, polycystic kidney disease is prevalent in dogs and cats.
- In certain embodiments, the subject of the method will be a subject in need of treatment for a selected condition. For example, the subject may be a subject suffering from a condition, may be symptomatic of a selected condition, or may be at risk of a selected condition.
- The methods of the invention encompass the ingestion and administration of ketonic agents in a biologically or therapeutically effective amount. In one measure, a biologically or therapeutically effective amount is an amount of ketonic agent ingested as dietary supplement or administered therapeutically that is sufficient to induce a ketonic response. Such a response may be indicated by assaying the elevated blood concentration of a ketone body such as BHB. A response could also be measured by assaying a change in the blood levels of fatty acids that can be used as an indicator of the anti-lipolytic consequences of GPR109a activation. In one measure, a ketonic response is the elevation of ketones in the blood or other compartment of the subject, for example, any significant elevation compared to subjects not experiencing ketosis. In one measure, a ketonic response is the increase in GPR109A activation in selected target cells of the subject, for example, any significant increase in GPR109A activity compared to subjects not ingesting or administered a ketonic agent. In one measure, a ketonic response is the attainment of a specific physiological outcome or state, for example, the mean or median dosage required to attain the selected outcome in a significant portion of representative subjects, compared to subjects not ingesting or administered the ketonic agent. Selected outcomes may encompass any relevant outcome, such as reduced symptoms of a selected condition, for example, reduced size or abundance of cysts in the case of cystic disease, improved organ or cellular function, and other physiological or health measures.
- The dietary supplements and therapeutic ketonic agents of the invention are ingested or administered in a dose, being an amount of ketonic composition ingested or otherwise received at a time or over a specified timeframe (e.g. a daily dose). Doses may be referred to as approximate amounts, for example, being “about X mg.” “About,” as used herein means, in various embodiments, within plus-or-minus 10%, plus-or-minus 5%, or plus-or-minus 1% of the enumerated value.
- In various embodiments, the ingested or administered ketonic composition is BHB, or a BHB analog, e.g. a BHB precursor, configured for oral administration, wherein the administration is oral, and the biologically effective or therapeutically effective dosage is in the range of 0.1 to 50 grams BHB per day, e.g., for humans. For example, daily doses of about or at least 100 mg, about or at least 250 mg, about or at least 500 mg, about or at least 1 gram, about or at least 2 grams, about or at least 3 grams, about or at least 4 grams, about or at least 5 grams, about or at least 6 grams, about or at least 7 grams, about or at least 8 grams, about or at least 9 grams, about or at least 10 grams, about or at least 12 grams, about or at least 15 grams, or about or at least 20 grams may be ingested or administered. In some embodiments, the dosage of BHB, BHB analog, including BHB precursors, is in the range of 10-200 mg/Kg body weight, for example, 10, 25, 50, 75, 100, 125, 150, 175, or 200 mg./Kg. For non-human animal subjects, such as animal models or pets, the exemplary dosages above may be adjusted based on the difference in body weight or body surface area. In one embodiment, the non-human is a small animal (e.g. rodent, dog, or cat) and the biologically or therapeutically effective amount of BHB or BHB analog is in the range of 10-150 mg/Kg, in various embodiments, for example, being about 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 100, 120, 150 mg/Kg.
- In an alternative measure, the biologically effective or therapeutically effective amount of BHB or BHB analog is determined as the amount necessary to raise blood ketone levels (e.g., BHB levels) to a selected threshold indicative of ketosis, for example, a dose sufficient to attain a blood concentration of BHB at least 0.250 to 5 mMol BHB per liter of blood, for example, about or at least 0.250, about or at least 0.500, about or at least 0.750, about or at least 1.0, about or at least 2.0, about or at least 3.0 mMol BHB per liter of blood.
- In the case of GPR109A activators, the biologically or therapeutically effective dose will be determined by the potency, ADMET, and delivery route of the selected GPR109A activator. This class of compositions includes potent small molecules that act in the picomolar to nanomolar range, as well as ketones and other orally available compositions (e.g. niacin) that require higher concentrations to induce GRP109A activation in selected target cells (e.g. cyst epithelial cells). Accordingly, the biologically or therapeutically effective dose of GPR109A activator may be determined by one of skill in the art based on the properties of the agent and the desired therapeutic outcome.
- In the case of a combination product comprising a crystal precipitation inhibitor, e.g. citrate, a biologically or therapeutically effective amount is an amount of crystal precipitation inhibitor ingested or administered that is sufficient to inhibit crystal formation in vivo, e.g. uric acid crystal formation or calcium crystal formation, or sufficient to induce conditions that inhibit crystal formation, such as increased urinary concentration of citrate to antagonize calcium crystal precipitation, or increased urinary pH to antagonize uric acid crystal precipitation, or reduced blood or urine levels of uric acid to antagonize uric acid crystal precipitation.
- In various embodiments, the selected crystal precipitation inhibitor, for example, citrate, is configured for oral administration, the administration is oral, and, for example in humans, the biologically or therapeutically effective dose ingested or administered may be in the range of 100 mg to 15 grams, for example, at least or about 100 mg, at least or about 200 mg, at least or about 300 mg, at least or about 500 mg, at least or about 1 gram, at least or about 2 grams, at least or about 3 grams, at least or about 4 grams, at least or about 5 grams, at least or about 6 grams, at least or about 7 grams, at least or about 8 grams, at least or about 9, grams, or at least or about 10 grams. In some embodiments, the dosage of citrate or citrate analog is in the range of 5-100 mg/Kg body weight, for example, in various embodiments, being 5, 10, 20, 25, 30, 40, 50, 55, 65, 70, 75, 80, 85 90, or 100 mg/Kg. For non-human animal subjects, such as animal models or pets, the exemplary dosages above may be adjusted based on the difference in body weight or body surface area. In one embodiment, the non-human is a small animal (e.g. rodent, dog, or cat) and the biologically or therapeutically effective amount of citrate or citrate analog is in the range of 10-100, for example, 25-75 mg/Kg, in various embodiments, for example, being about 10, 20, 30, 40, 45, 50, 55, 60, 65, 70, 80, 90 or 100 mg/Kg.
- The dosage of the crystal precipitation inhibitor, e.g., citrate, in the dietary supplement may be determined by alternate measures. For example, in one embodiment, the crystal precipitation inhibitor, such as citrate, is ingested or administered at a dosage of between 0.1 mmol- 10 mmol/100 g body weight per day, for example, at least 0.5, at least 1, at least 2, at least 5, at least 7.5 or at least 10 mmol/100 g body weight per day. In another embodiment, the crystal precipitation inhibitor, such as citrate, is ingested or administered at a dosage of between 0.5 to 10 mg/citrate or citrate salt per m2 body area per day, for example at least 1, at least 2, at least 3, at least 4, or at least 5 mg per m2 body area, per day.
- Doses may be ingested or administered according to a selected health or treatment regimen. In some embodiments, doses are ingested or administered for a selected period of time, e.g. a period of days, weeks, or months. In some implementations, especially in preventative methods, chronic, long-term ingestion or administration is contemplated for maintaining beneficial, therapeutic, or preventative effects. In a primary embodiment, the administration is daily with one or more dosages ingested or administered per day.
- Multiple such dosages may be administered during the day, to arrive a cumulative dosage near, at, or above the biologically effective or therapeutically effective daily dosage, for example, two, three, four, or more doses per day. Dosage forms (e.g. capsules, packets of dissolvable powder for drinks, scoops for measuring such powder, etc.) may be configured for fractions of the daily dose. In some implementations, two or more dosages are delivered per day, for example, a morning and an evening dose, a dosage administered before or after each meal, a dosage delivered every four hours, six hours, twelve hours, or at other selected time intervals. Advantageously, a low dosage of BHB, administered multiple times per day, may be more palatable than a full daily dosage, wherein the unpleasant taste of BHB is an issue. Likewise, by administering low dosages of citrate over multiple daily administrations, gastrointestinal issues associated with long term citrate consumption can be alleviated. In alternative embodiments, the dietary supplement is consumed at less than daily frequency, for example, once a week, twice a week, three times a week, etc.
- Exemplary Dietary Supplements and Therapeutic Compositions. The methods of the invention will encompass the administration or ingestion of ketonic compositions in a dietary supplement or a therapeutic composition. The dietary supplement or therapeutic composition may comprise any of the ketonic compositions, combination products, and formulations, as disclosed in the previous sections, In various embodiments, the dietary supplement or a therapeutic composition comprises an exemplary formulation as forth below.
- The dietary supplement or a therapeutic composition will comprise a ketonic composition. The ketonic composition may comprise one or more of BHB, a BHB analog, a GPR109A agonist, or a combination of the foregoing. The formulations may comprise a combination of two or more different ketonic compositions. In some embodiments, ketonic composition comprises a BHB analog, wherein the BHB analog may comprises an ester of BHB, a BHB precursor, 1,3-butanediol, or a bi-functional composition comprising one or more molecules of BHB, a BHB analog, and/or a GPR109A agonist conjugated to one or more molecules of citrate. In some embodiments, the bi-functional molecule is
Structure 5,Structure 6,Structure 7, orStructure 8. In some embodiments, the composition comprises L-BHB, for example, at least 10% L-BHB, about 50% L-BHB, or substantially pure L-BHB. In some embodiments, the ketonic composition comprises a GPR109A agonist, wherein the GPR109A agonist comprises a composition selected from the group consisting of niacin, a niacin analog, clotrimazole, GSK256073, MK-1903, monomethylfumarate acipimox, acifran, 3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4-carboxylic acid pyrazine-2-carboxylic acid, LUF6281, LUF6283, a pyrazolyl propionyl cyclohexenamide, an acyl hydroxypyrazole, and SCH900271. - The dietary supplement or therapeutic composition will comprise a ketonic composition in a biologically or therapeutically effective amount. In some embodiments, the biologically or therapeutically effective amount is an amount sufficient to attain blood ketone levels at a level indicative of ketosis, for example, a dose sufficient to attain a blood concentration of BHB at least 0.250 to 5 mMol BHB per liter of blood, for example, about or at least 0.250, about or at least 0.500, about or at least 0.750, about or at least 1.0 mMol BHB per liter. In various embodiments, the ketonic agent comprises BHB and the biologically or therapeutically effective amount is an amount in the range of 0.1 to 50 grams BHB, for example, 0.1 to 50 grams BHB per day. In various embodiments the biologically or therapeutically effective amount is about or at least 100 mg, about or at least 250 mg, about or at least 500 mg, about or at least 1 gram, about or at least 2 grams, about or at least 5 grams, or, about or at least 10 grams.
- In various embodiments the dietary supplement or therapeutic composition will comprise a ketonic composition in combination with a biologically or therapeutically effective amount of a crystal precipitation inhibitor. In one embodiment, the biologically or therapeutically effective amount of a crystal precipitation inhibitor is an amount sufficient to inhibit in vivo crystal precipitation, for example, sufficient to inhibit the formation of calcium oxalate crystals, the formation of calcium phosphate crystals, and/or the formation of uric acid crystals. In some embodiments, the crystal precipitation inhibitor is a calcium chelator. In some embodiments, the crystal precipitation inhibitor is a buffering agent or pH-modulating or alkanizing agent.
- In various embodiments the crystal precipitation inhibitor is selected from the group consisting of citrate, hydroxycitrate, esters of citric acid (e.g. monoester, diester, triester), amides of citric acid, 1,3 dioxal-4-ones, sidophores, peroxycitric acid, hydroxycitrate, and tricarballylic acid, a composition that alkanizes urine, a carbonate or bicarbonate, magnesium carbonate or bicarbonate, calcium carbonate or bicarbonate, or sodium carbonate or bicarbonate, allopurinol, oxypurinol and febuxostat, inhibitors of xanthine oxidase, Lesinurad, Rasburicase, and a calcium chelator. In one embodiment the crystal precipitation inhibitor is citrate. In various embodiments, the biologically effective biologically or therapeutically effective amount is at least 100 mg citrate, for example, 200 mg citrate per day, at least 500 mg citrate, for example, 500 mg citrate per day, citrate at a weight percentage in the dietary supplement or therapeutic composition of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
- In various embodiments the dietary supplement or therapeutic composition will comprise a ketonic composition in combination with a biologically or therapeutically effective amount of a lipotoxic agent. In one embodiment, the biologically or therapeutically effective amount of a lipotoxic agent is an amount sufficient to cause lipotoxic effects in glucose-dependent cells, e.g., PKD cyst epithelial cells. in various embodiments, biologically or therapeutically effective amount of a lipotoxic agent is in the range of 0.5-100g per day, for example about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 90 g per day. In one embodiment, the lipotoxic agent comprises MCT. In one embodiment, the lipotoxic agent comprises fatty acids.
- In one embodiment, the dietary supplement or therapeutic composition comprises a ketonic composition in combination with both a biologically or therapeutically effective amount of a crystal precipitation inhibitor and a biologically or therapeutically effective amount of a lipotoxic agent.
- The dietary supplements of the invention are by definition formulated for oral delivery. In various embodiments, the therapeutic compositions may also be formulated for oral delivery. In one embodiment, the therapeutic composition is formulated for oral delivery as a dietary supplement. In various embodiments the dietary supplement or therapeutic composition is formulated as a capsule, a chewable tablet, a tablet, a dissolvable powder, a beverage, or a food item.
- In the case of dietary supplements or therapeutic compositions comprising a ketonic composition in combination with a secondary agent (e.g. a crystal precipitation inhibitor such as citrate or a lipotoxic agent such as unsaturated fatty acids), the dietary supplement or therapeutic composition may be formulated as a single product containing both the ketonic composition (e.g. BHB or BHB analog) and the secondary agent so that only a single product is required to be ingested or administered. In another embodiment, the ketonic composition and the secondary agent(s) (e.g. a crystal precipitation inhibitor such as citrate or a lipotoxic agent) are provided together in separate dosage forms, for example, capsules or chewable tablets, for example, to be ingested at the same time.
- Methods of Supporting Health by the Use of Dietary Supplements. In one aspect, the scope of the invention encompasses novel methods of promoting health and wellness by the use of dietary supplements comprising ketonic compositions. In various embodiments, the function of the compositions and methods of the invention will be described as “supporting health,” for example, “supporting renal health.” As used herein, supporting a enumerated type of health will encompass any activity that maintains, enhances, improves, or promotes relevant organ or cellular function, for example, renal function in the case of supporting renal health. In various embodiments, the support of health is achieved by ameliorating the risk, progression, and/or severity of a condition. Ameliorating the risk, progression, and/or severity of a condition may encompass any number of physiological, health, or medical processes, such as treating or preventing the condition in any way, reducing, reversing, or curing symptoms, pathologies, or pathological processes of the condition, slowing or halting the progression of the condition, or any other therapeutic or beneficial effect.
- Methods of Treatment. Certain methods of the invention encompass the prevention or treatment of a selected condition. As used herein, treatment will encompass any number of therapeutic effects and outcomes with respect to a selected condition, including, for example: a reduction in the severity of symptoms of the condition; the inhibition of pathological processes underlying the condition; the reversal of pathological events or processes of the condition; halting or slowing the progression of the condition; or a reduction in morbidity and/or mortality associated with the condition. Treatment, as used herein, will further encompass prevention of an enumerated condition. As used herein, prevention will encompass any number of actions with respect to a selected condition, for example: preventing the onset of the condition; reducing the probability of the condition occurring; halting the further progression of the condition, ameliorating underlying physiological parameters that promote the condition, or any other preventative action. As used herein, treatment will further encompass enhancements of target cell or organ function, such as quantitatively or qualitatively improved function, for example, in certain implementations, improved function, restoring normal function, or maintaining function.
- Methods of Supporting Renal Health and Treating Renal Conditions. In a primary aspect, the scope of the invention encompasses the use of ketonic compositions in dietary supplements and therapeutic compositions to address various aspects of renal health and renal conditions.
- In one implementation, the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting renal health in a subject. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of renal health. In a related implementation, the scope of the invention encompasses a method of supporting renal health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition. In various embodiments, the dietary supplement comprises a ketonic composition in combination with a crystal precipitation inhibitor and/or a lipotoxic agent. In one embodiment, supporting renal health means maintaining or enhancing one or more measures of renal function. For example, renal function may be assessed by glomerular filtration rate, creatine clearance rate, urine output, proteinuria, or other measures of renal function known in the art. In one embodiment, supporting renal health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more renal conditions.
- In various embodiments, the scope of the invention further encompasses the use of therapeutic compositions comprising ketonic compositions for the treatment of renal conditions. In one embodiment, the scope of the invention encompasses a ketonic composition for use in a method of treating a renal condition. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of a renal condition. In one embodiment, the scope of the invention encompasses a method of treating a renal condition in a subject in need of treatment therefor by administering to the subject a therapeutically effective amount of a ketonic composition. The ketonic composition may be delivered or provided in a therapeutic composition, for example, a formulation comprising other components and/or active ingredients. In some embodiments, the dietary supplement comprises a ketonic composition in combination with a crystal precipitation inhibitor and/or a lipotoxic agent. In some embodiments, the treatment is a preventative treatment.
- In the practice of the foregoing methods, the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of renal health support, for example, a subject having or at risk of a renal condition. A renal condition, as used herein, may encompass any pathological process, pathological state, disease, or dysfunction of the kidney. In various embodiments, for example, the subject is a human, a cat, or a dog.
- In various embodiments, the renal condition is a cystic condition. In one embodiment, the cystic condition is PKD. In various embodiments, supporting renal health and/or treatment of a cystic conditions encompasses preventing or ameliorating any pathological effects of renal cysts, reducing or preventing the formation of renal cysts, reducing the number and/or size of renal cysts, slowing the growth rate of renal cysts, or eliminating renal cysts. In one embodiment, the cystic condition is ADPKD. In one embodiment, the polycystic kidney disease is autosomal recessive polycystic kidney disease (ARPKD). In various embodiments, the subject to which the dietary supplement or therapeutic composition is administered is a subject having PKD or at risk of PKD. In some embodiments, the subject at risk of PKD is a subject carrying a mutation in any of PKD1, PKD2, PKD3, or other genes wherein mutations increase the risk of PKD. In some embodiments, the subject at risk of PKD is a subject with health or demographic factors associated with PKD risk. In some embodiments, the subject is a human. In some embodiments, the subject is a dog or cat.
- In other embodiments, the renal cystic condition is a condition selected from the group consisting of renal cysts as found in tuberous sclerosis complex, medullary cystic kidney disease, Acquired Cystic Kidney Disease, including acquired simple renal cysts, cystic renal cell carcinoma, and cystic nephroma.
- In one embodiment, the renal condition is acute kidney injury (AKI). AKI encompasses kidney dysfunction or failure, and may be caused by many factors or causative agents. AKI manifests as damage to kidneys and impaired kidney functions, including progression along the RIFLE staging criteria known in the art, encompassing risk, injury, failure, loss, and end-stage renal disease. In various embodiments, the subject to which the dietary supplement or therapeutic composition is administered is a subject having or at risk of AKI. In various embodiments, a subject at risk of AKI is a subject having systemic disease, trauma, sepsis, renal artery stenosis, renal vein thrombosis, urinary tract obstruction, glomerulonephritis, acute tubular necrosis, acute interstitial nephritis, or liver cirrhosis. In various embodiments, a subject at risk of AKI is a subject having reduced blood flow to kidneys, such as by cardiac dysfunction or failure, surgery, trauma or ischemia. In various embodiments, a subject at risk of having AKI is a subject likely to be exposed to or being exposed to harmful levels of nephrotoxins such as mercury or platinum compounds, radiological contrast agents, and antibiotics. In one embodiment, the subject at risk of AKI is a subject likely to have or scheduled to have surgery, in one embodiment, cardiac surgery. In various embodiments, dietary supplement and/or therapeutic composition is administered as a pre-treatment prior to surgery and/or post-treatment after surgery in order reduce the risk or severity of AKI and to reduce the risk of developing complications therefrom, including chronic kidney disease.
- In various embodiments, the renal condition is chronic kidney disease (CKD), encompassing any gradual loss or long-term impairment of kidney function. In various embodiments, the subject to which the dietary supplement or therapeutic composition is administered is a subject having or at risk of CKD. A subject at risk of CKD may be a subject having any known risk factor of CKD including, Type I or Type II diabetes mellitus, prior occurrence of acute kidney injury, glomerulornephritis, high blood pressure, or family history of CKD.
- In various embodiments, the renal condition is a condition selected from the group consisting of: diabetic nephropathy, nephronophthisis, Meckel-Gruber syndrome, Bardet-Biedl syndrome, Joubert syndrome, medullary sponge kidney, multicystic dysplastic kidney, Dent's disease, Glomerulocystic kidney disease, Von Hippel-Lindau Syndrome, and mixed epithelial and stromal tumor of the kidney.
- Methods of Supporting Health and Treating Reperfusion Injury. In another aspect, the methods of the invention are directed to various conditions described as ischemic reperfusion injuries (IRI), sometimes referred to as reoxygenation injury. This class of pathologies is associated with the loss of blood flow in the affected organ, structure, or area. The hypoxia and loss of nutrients in the affected area promotes conditions wherein the subsequent restoration of circulation results in inflammation and damage caused by severe oxidative stress. The loss of circulation may be the result of trauma, injury, ischemic events, cardiac failure, or other causes. Surgery is also a causative agent of IRI, especially cardiac surgery, wherein reduced blood flow during the procedure facilitates IRI upon restoration of normal blood flow. IRI may affect any number of tissues, including the arteries and veins, brain, heart, liver, lungs, kidneys, skeletal muscle, and digestive tract.
- In one implementation, the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting health with regards to ischemic reperfusion injury. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of health with regards to ischemic reperfusion injury. In a related implementation, the scope of the invention encompasses a method of supporting health with regards to ischemic reperfusion injury in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition. In various embodiments, the dietary supplement may comprises a ketonic agent in combination with a crystal precipitation inhibitor. In one embodiment, supporting health with respect to ischemic reperfusion injury means maintaining or enhancing one or more measures of organ function, for example, function of the brain, heart, liver, lungs, kidneys, skeletal muscle, or digestive tract. In one embodiment, supporting health with respect to ischemic reperfusion injury in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more ischemic reperfusion injury conditions.
- In another aspect, the scope of the invention encompasses the use of therapeutic compositions comprising ketonic compositions for the treatment of ischemic reperfusion injury conditions. In one embodiment, the scope of the invention encompasses a ketonic composition for use in a method of treating an ischemic reperfusion injury condition. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of ischemic reperfusion injury. In one embodiment, the scope of the invention encompasses a method of treating a ischemic reperfusion injury condition in a subject in need of treatment therefor by administering to the subject a therapeutically effective amount of a ketonic composition. The ketonic composition may be delivered or provided in a therapeutic composition, for example, a formulation comprising other components and/or active ingredients. In some embodiments, the therapeutic composition comprises a ketonic composition in combination with a crystal precipitation inhibitor. In some embodiments, the treatment is a preventative treatment.
- In the foregoing methods of the invention, the subject to which the dietary supplement or therapeutic composition comprising a ketonic composition is administered is a subject in need of treatment for one or more ischemic reperfusion injuries, in some embodiments being a subject that has experienced, or is at risk of the one or more ischemic reperfusion injuries. In one embodiment, the subject at risk of ischemic reperfusion injury is a subject likely or scheduled to undergo surgery. In one embodiment, the dietary supplement or therapeutic composition is administered as a pre-treatment prior to surgery.
- Methods of Supporting Neurological Health and Treating Neurodegenerative Conditions. In various implementation, the methods of the invention are directed to maintaining or improving some aspect of neurological health, and to addressing neurological conditions, including conditions of the brain, central nervous system, and peripheral nervous system.
- In one implementation, the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting neurological health. In a related implementation, the scope of the invention encompasses a method of supporting neurological health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a therapeutically effective amount of a dietary supplement comprising a ketonic composition. In one embodiment, supporting neurological health means maintaining or enhancing one or more measures of neurological function, for example, cognitive function or motor function. In one embodiment, supporting neurological health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more neurological conditions.
- In another implementation, the scope of the invention encompasses therapeutic compositions comprising a ketonic composition for use in a method of treating a neurological condition. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for treatment of a neurological condition. In a related embodiment, the scope of the invention encompasses a method of treating a neurological condition in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising a ketonic composition. In some embodiments, the therapeutic composition further comprises a crystal precipitation inhibitor and/or a lipotoxic agent. In some embodiments, the treatment is a preventative treatment.
- In the foregoing methods, the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of treatment for one or more neurological conditions. A neurological condition, as used herein, may encompass any pathological process, pathological state, disease, or dysfunction of the central or peripheral nervous system, especially conditions that affect the brain, for example, a neurodegenerative disease. In various embodiments, the subject at risk of a neurological condition is has, or is at risk of the one or more neurological conditions. In one embodiment, the neurological condition is a neurodegenerative condition. In various embodiments, the neurological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, chronic traumatic encephalopathy, age-related neurodegeneration, frontotemporal dementia, and retinitis pigmentosa.
- Methods of Supporting Cilial Health and Treating Ciliopathies. In some embodiments, the methods of the invention are directed to health aspects and conditions associated with the cilia. Cilia are a component of almost all vertebrate cells. Ciliopathies encompass a large group of disorders associated with cilial dysfunction, typically driven by genetic mutations encoding defective proteins which result in either abnormal formation of cilia or which disrupt their normal function. Ciliopathies include a wide array of conditions across various organs and systems of the body.
- In one implementation, the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of supporting cilial health. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the support of cilial health . In a related implementation, the scope of the invention encompasses a method of supporting cilial health in a subject by the administration to the subject (for example, including self-administration, i.e. ingestion) of a biologically effective amount of a dietary supplement comprising a ketonic composition. In one embodiment, supporting cilial health means maintaining or enhancing one or more measures of cilial function. In one embodiment, supporting cilial health in a subject is achieved by ameliorating the subject's risk, progression, and/or severity of one or more ciliopathies.
- In another implementation, the scope of the invention encompasses a therapeutic compositions comprising a ketonic composition for use in a method of treating a ciliopathy. In a related embodiment, the scope of the invention encompasses the use of a ketonic composition in a method of making a medicament for the treatment of a ciliopathy. In a related embodiment, the scope of the invention encompasses a method of treating a ciliopathy in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising a ketonic composition. In some embodiments, the therapeutic composition further comprises a crystal precipitation inhibitor and/or a lipotoxic agent. In some embodiments, the treatment is a preventative treatment to a subject at risk of a ciliopathy.
- In the foregoing methods, the subject to which the dietary supplement or therapeutic composition is administered may be a subject in need of treatment for one or more ciliopathies, in some embodiments being a subject that has, or is at risk of the one or more ciliopathies. In various embodiments, the ciliopathy is selected from the group consisting of polycystic kidney disease, polycystic liver disease, retinitis pigmentosa, congenital fibrocystic diseases of the liver, diabetes, obesity, skeletal dysplasia's, Ahlstrom syndrome, Bardet-Biedl syndrome, Joubert syndrome, nephronophthisis,
orofaciodigital syndrome 1, Senior-Loken syndrome, primary ciliary dyskinesia, Jeune asphyxiating thoracic dysplasia, Marden-Walker syndrome, situs inversus or isomerism, retinal degeneration, agenesis of the corpus callosum, anencephaly, cerebellar vermis hypoplasia, Dandy-Walker malformation, diabetes, Ellis-van Creveld syndrome, exencephaly, eye movement abnormalities, hypoplasia of the corpus callosum, hypotonia, sterility, Jeune asphyxiating thoracic dystrophy, Juvenile myoclonic epilepsy, Marden-Walker syndrome, Meckel-Gruber syndrome, sensorineural deafness, and spina bifida. - Other Uses of Dietary Supplements. In various embodiments, the dietary supplements and therapeutic compositions comprising ketonic agents may be utilized in methods of preventing or treating conditions such as cancer, a cystic condition of the liver, a pulmonary disease, autoimmune disease, a condition of the digestive tract, epilepsy, or infection.
- In one embodiment, the dietary supplements and therapeutic compositions of the invention are used in the treatment of viral infection. It has been shown in the art that ketosis may increase the body's ability to fight viral infections, for example, as described in Goldberg et al., Ketogenic diet activates protective γδ T cell responses against influenza virus infection. Science Immunology, 2019; 4 (41): eaav2026. In one embodiment, the scope of the invention encompasses a dietary supplement comprising a ketonic composition for use in a method of preventing or treating viral infection. In one embodiment, the scope of the invention encompasses a method of treating a viral infection, for example, preventing viral infection, in a subject by the administration to the subject of a therapeutically effective amount of a therapeutic composition comprising a ketonic composition. The viral infection may an infection caused by any pathogenic virus, for example influenza viruses, coronaviruses such as COVID19, HIV, noroviruses, respiratory syncytial viruses, herpes viruses, and papillomaviruses.
- A key signaling molecule activated in ADPKD is the kinase mammalian target of rapamycin (mTOR) that regulates many cellular behaviors including proliferation, cell growth, and energy metabolism and is responsive to growth factors, cellular energy status, and nutrient availability. mTOR inhibitors, such as rapamycin, were highly effective in PKD rodent models but failed in subsequent clinical trials, most likely due to dose-limiting, significant extra-renal side effects and toxicities.
- As an alternative to pharmacological intervention, modulation of mTOR activity in the kidney via dietary intervention was explored, since mTOR is under control of nutrient availability. As reported in Kipp, et al. (2016). A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am. J. Physiol. Renal Physiol. 310, F726-F731 , a very mild reduction in food intake, by only 23%, profoundly inhibited renal cyst growth and mTOR activity while not affecting body weight gain. Another study, using two different orthologous mouse models, had similar conclusions and showed that food restriction by 40%, and even by only 10%, significantly inhibited renal cyst growth, as reported in Warner, et al., (2016). Food restriction ameliorates the development of polycystic kidney disease. J. Am. Soc. Nephrol. 27, 1437-1447. These results raise questions about the mechanism underlying the beneficial effect of dietary restriction, including whether the inhibition of renal cyst growth was due to overall caloric restriction or due to the restriction of a particular macro- or micro-nutrient, or by a different mechanism entirely.
- As set forth herein, dietary restriction strongly inhibits renal cyst growth due to metabolic changes caused by intermittent fasting. Time-restricted feeding, in comparison to isocaloric ad libitum feeding, causes an intermittent decrease of blood glucose and an increase in ketogenesis and leads to strong inhibition of renal cyst growth, proliferation, and fibrosis. These effects are not merely due to circadian feeding rhythm because ad libitum administration of a ketogenic diet (KD) similarly inhibits renal cyst growth. Herein is shown that acute fasting in mouse, rat, and feline models of PKD induces significant apoptosis in cyst-lining epithelial cells and a striking reversal of renal cystic burden. Finally, it is shown herein, surprisingly, that supplementation of diet with just the natural ketone BHB replicates the beneficial effects of dietary restriction. These results indicate that dietary restriction has profound inhibitory effects on PKD progression, and this depends on induction of ketosis, as renal cyst cells in PKD appear to be metabolically inflexible and thus unable to adapt to alternative fuel sources. These results demonstrate that disease progression in ADPKD can be controlled by dietary interventions such as time-restriction or KDs and also, unexpectedly, by BHB supplementation or treatments that replicate BHB action.
- Glucose Levels Predict the Rate of Kidney Volume Change in Individuals with ADPKD. Individuals with ADPKD and
type 2 diabetes have significantly larger total kidney volume (TKV) than those with ADPKD alone, and overweight or obesity associates with faster progression in early-stage ADPKD. To investigate whether serum glucose levels even in normoglycemic, serum glucose was explored in a cohort of human ADPKD subjects with preserved renal function. Baseline serum glucose in this cohort uniquely predicted a greater TKV and htTKV increase over time. Similar analyses found no effect of the baseline serum glucose on average yearly change in GFR. Together, these results suggest that glucose availability may directly affect renal cystic disease progression in ADPKD and that limiting glucose availability may ameliorate cystic progression in PKD. - Han:SPRD rats, a non-orthologous model of PKD with a mutation in Anks6 were placed on a time-restricted feeding (TRF) regime wherein TRF animals had access to food for an 8-h period within their 12-h dark cycle. Animals were treated for 5 weeks from post-natal weeks 3-8. TRF animals consumed a comparable number of calories and gained weight similar to the AL controls, indicating that TRF does not lead to food or caloric restriction, and there were no negative effects measured on any other organ. After 5 weeks of this dietary regimen, animals in the TRF cohort exhibited strikingly reduced renal cystic disease progression compared to animals in the AL cohort. Kidneys of TRF-treated animals were significantly less cystic (
FIG. 2A ) with a marked reduction in the 2-kidney/body weight ratio and improved kidney function as indicated by normalization of serum creatinine. In whole kidney sections, total cyst number (FIG. 2B ) and cyst size (FIG. 2C ), were decreased in TRF animals compared to controls, demonstrating that TRF inhibited both cystogenesis and cyst expansion. Additionally, TRF-treated animals had increased levels of BHB and reduced blood glucose indicative of ketosis. - TRF Reduces mTORC1 and STAT3 Signaling, Interstitial Fibrosis, and Proliferation in Cystic Kidneys. Changes in known PKD associated pathways and pathologies were assessed. A significant reduction in phosphorylated S6S235/236 (
FIG. 3 ) a downstream target in the mTOR pathway, was observed in cyst-lining epithelial cells of TRF-treated male, but not female, Cy/+ animals indicating inhibition of mTORC1 activity. PKD is known to lead to interstitial fibrosis, a hallmark of progressive renal disease. Collagen deposition was markedly reduced in TRF compared to AL animals. Myofibroblasts were strongly reduced and frequently absent in kidneys of TRF animals. Staining with the cell cycle marker Ki-67 revealed a significant reduction in cyst-lining cells in TRF compared to AL animals, indicating inhibition of proliferation. Active, phosphorylated STAT3, which has previously been shown to be activated in PKD and drives cystic progression, was reduced or absent in cysts in TRF-treated animals. - A KD Ameliorates Disease Progression in Juvenile Han:SPRD Rats. Han:SPRD rats were given ad libitum access to a high-fat, very-low-carbohydrate keto diet (KD- caloric ratio of 91% fat, 2% carbohydrates, and 5% protein) and compared to animals with ad libitum access to NC (caloric ratio of 62% carbohydrates, 25% protein, and 13% fat). Animals were treated again for 5 weeks from post-natal weeks 3-8. Renal cystic disease progression was strongly inhibited in animals on the KD regimen compared to those on NC along with a remarkable reduction in the 2-kidney to body weight and cystic area (
FIG. 4A ). KD-treated rats exhibited decreased blood glucose and increased BHB levels compared to NC controls, and the level of ketosis was more profound than that achieved with the TRF regimen. Animals on the KD appeared phenotypically normal and did not exhibit any signs of distress during the study. However, KD-treated animals exhibited reduced body weight gain, and only gained approximately 2%-10% of their body weight each week during the study. This lack of growth was not dependent on caloric intake, as the KD group consumed comparable calories to NC controls relative to their body weight, likely resulting from protein restriction. KD had a disproportionate inhibitory effect on the growth of poly-cystic kidneys as compared to normal kidneys. Importantly, KD feeding led to improved kidney function (FIG. 4B ) as well as inhibited both cystogenesis (FIG. 4C ) and cyst expansion (FIG. 4D ). - The effects of KD treatment on PKD progression were generally similar to those caused by the TRF treatment. mTOR (
FIG. 5 ) and STAT3 activity in cystic epithelia were both blunted in KD-fed rats. SMA1-positive myofibroblasts were less in KD-fed animals compared to NC controls and was accompanied by a decrease in collagen deposition and the percent of Ki-67-positive demonstrating inhibition of cell cycle entry and proliferation (FIG. 6A ). It was also found that KD feeding increased the levels of phospho-AMPK in the kidneys of cystic animals and increased CPT1a levels in male cystic, but not female cystic, rats (FIG. 6B and 6C ). - A KD Ameliorates Disease Progression in Adult Han:SPRD Rats. Han:SPRD rats at an older age (post-natal week 8-12) were fed KD versus NC. At this age, there is no longer cystic kidney enlargement, and no further change in kidney size was observed. During the treatment period, weight gain was mildly affected in rats on the KD, and there was no difference between wild-type and cystic animals. In contrast, the total mass of polycystic kidneys remained nearly the same in animals on NC but lowered by 35% in male rats on KD, accompanied by diminished 2-kidney to body weight ratio and percent cystic area (
FIG. 6A ). Similar to the juvenile experiments, the KD again affected the organ size of polycystic kidneys disproportionally because wild-type kidneys or other organs, such as the heart, were largely unaffected. Unlike the juvenile experiments, serum creatinine was unaffected by KD treatment in adult rats as was the total number of cysts per animal (FIG. 6B ). There was, however, a marked reduction in cyst size (FIG. 6C ), indicating that KD feeding prevents cyst growth in animals at that age. KD feeding led to a reduction in fibrosis in male animals, as indicated by reduced collagen, but there was no detectable difference in myo- fibroblasts, mTOR activity, or the cell cycle marker Ki-67. - Acute Fasting Leads to Cell Death and Renal Cyst Regression in Multiple PKD Animal Models. The strong inhibitory effects on PKD progression was observed with ketosis induced by TRF and KD regimens during the course of several weeks. To investigate whether ketosis has any fast-acting effects on renal cysts, Han:SPRD rats were subjected to acute ketosis via fasting. 8-week- old animals were fasted for 48 h with free access to water. As expected, acute fasting led to decreased blood glucose and increased blood BHB values (
FIGS. 7A and 7B ), indicating the induction of ketosis. The fasting-induced modest decrease in body weight (12%) is expected due to depletion of fat and glycogen reserves, primarily in adipose tissue, liver, and skeletal muscle, respectively, and was consistent between wild-type and cystic animals. Strikingly, acute fasting strongly affected cystic kidneys, leading to a 20% reduction in cystic area (FIG. 7C ) and a concurrent reduction in kidney mass and the 2-kidney/heart weight ratio. Fasting had minimal-to-no effect on the weight of hearts and normal kidneys as expected, indicating that the fasting effects are specific to PKD kidneys. The loss of mass was not due to any loss of glycogen, and the reduction of cystic volume accounted for the observed loss in kidney mass, demonstrating that acute fasting leads to a loss of cyst fluid. - TUNEL staining revealed that acute fasting led to greater cell death of cystic cells but did not cause greater cell death in normal, non-cystic kidneys. In particular, there was a conspicuous number of TUNEL-positive, detached cells in cyst lumens, indicating that these dead cells originated from sloughed-off cyst-lining cells. Renal cysts in fasted animals frequently exhibited fragmented cells and denuded epithelium, which was not observed in renal cysts of control-fed cystic animals, demonstrating that loss of cyst fluid caused by acute fasting is due to cell death and disruption of the epithelial barrier of cysts, leading to draining of cyst fluid, presumably via the interstitium and lymphatics, leading to overall shrinking of polycystic kidneys.
- Next was explored the possibility that increased supply of fatty acids during ketosis may affect cystic cells. As expected, intracellular oil droplets are rarely observed in normal or cystic kidneys in control-fed animals while acute fasting leads to accumulation of oil droplets in tubule cells in normal kidneys consistent with previous reports. Cyst-lining cells in polycystic kidneys exhibited a much exaggerated degree of cytoplasmic oil droplet accumulation. Frequently, most of the cytoplasm of the affected cells appeared to be occupied by oil droplets suggesting a state of severe steatosis. These findings demonstrate that cyst-lining cells have the ability to take up circulating fatty acids during acute fasting but are unable to sufficiently metabolize them, leading to lipotoxicity and greater cell death.
- To test acute ketosis in an orthologous mouse model of PKD, the orthologous Pkd1:Nestin-Cre model was used. Fasting for 24 h, with free access to water, led to a pronounced decrease in blood glucose and increase in blood BHB but no significant change in kidney mass or 2-kidney to body weight. TUNEL staining revealed that acute fasting induced apoptotic cell death in cyst-lining cells and greater TUNEL-positive luminal cells, in polycystic kidneys but not in normal kidneys. It is speculated that the short duration of fasting in mice is insufficient to lead to significant cyst draining and a measurable effect on cystic burden, as compared to rats.
- Oral BHB Treatment Prevents Polycystic Disease Progression in Juvenile Rats. To investigate if BHB might affect PKD progression, Han: SPRD rats were treated with BHB from post-natal weeks 3-8 in the context of ad libitum feeding with normal, high-carbohydrate chow (NC). BHB was administered as a sodium and potassium salt in the drinking water ad libitum at a dose equivalent to that recommended as a dietary supplement in BHB supplement drinks. Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB supplement (a mixture of NaCl/KCl). All treated animals consumed comparable amounts of water and calories, and BHB treatment had no effect on body weight or blood glucose levels. Surprisingly, after 5 weeks of treatment with BHB, the kidneys of PKD animals were nearly indistinguishable from kidneys of wild-type animals, both at the gross and histological level. BHB-treated PKD rats showed striking and unexpected reductions in the 2-kidney to body weight ratio and the cystic area (
FIG. 8A ) compared to water- and salt-treated controls. Neither wild-type kidneys nor other organs were affected by BHB treatment, indicating that the effect is specific to polycystic kidneys. Surprisingly, BHB treatment led to a strong reduction in fibrosis, almost complete elimination of myofibroblasts, improved kidney function (assessed by creatinine), and inhibition of proliferation. - These unexpected results demonstrate that BHB acts in a dominant fashion as a suppressor of PKD progression, even in animals that are fed a high-carbohydrate diet and have unaltered blood glucose levels. Altogether, our results demonstrate that inducing a state of ketosis, either by dietary intervention or surprisingly even by mimicking its effects with BHB, is an effective treatment for ADPKD in humans. A common factor in all of the interventions described herein was the elevation of BHB. Remarkably, treatment with BHB alone, even in the context of a normal high-carbohydrate rodent diet proved to be highly effective. Unexpectedly, this demonstrates that BHB itself is a major factor in suppressing PKD progression.
- The results also demonstrate that ketosis strongly inhibits not only renal cyst growth but also fibrosis. During the progression of PKD, cyst proliferation and fibrosis typically go hand in hand, and it is possible that both processes may reinforce each other. Myofibroblasts have been shown to be abundant in PKD kidneys and are thought to be a major contributor to fibrosis. Herein was demonstrated that ketosis greatly and unexpectedly reduces the abundance of pericystic myofibroblasts, especially the TRF regimen and BHB treatment, to almost complete absence. Consequently, overall fibrosis, as measured by collagen deposition, is strongly reduced.
- Most individuals with ADPKD in industrialized societies consume a high-carbohydrate diet throughout their waking hours and only rarely, if ever, experience periods of ketosis. A recent nutritional feasibility study recommends high-carbohydrate diets for individuals with ADPKD, as reported in Taylor, et al. (2017). Diet and polycystic kidney disease: a pilot intervention study. Clin. Nutr. 36, 458-466, as do many available cookbooks, websites, online forums, etc., where individuals with ADPKD may seek dietary advice. The results provided herein suggest that such dietary habits may worsen PKD progression. In contrast, moderation in caloric intake has been recommended for the management of ADPKD, as reported in Chebib, and Torres (2018). Recent advances in the management of autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 13, 1765-1776. The results presented herein, however, demonstrate that reducing caloric intake per se would not necessarily lead to inhibition of cystic progression but that the induction of the state of ketosis is instead important, irrespective of caloric intake.
- To investigate BHB, citrate, and combined BHB and citrate effects on PKD progression, Han:SPRD rats were treated with BHB or a combination of BHB and citrate from post-natal weeks 3-8 in the context of ad libitum feeding with normal, high-carbohydrate chow (NC). In the BHB treatments, BHB was administered as a sodium and potassium salt in the drinking water ad libitum at a dose equivalent to that recommended as a dietary supplement in BHB supplement drinks. In the citrate treatments, citrate was administered as a combination of tripotassium citrate and citric acid at a (0.82/1) ratio at a dose equivalent to that recommended utilized in citrate dietary supplements. Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB or BHB-citrate supplements (a mixture of NaCl/KCl). Control cohorts received either normal water or water supplemented with the molar equivalents of salt provided in the BHB or BHB-citrate supplements (a mixture of NaCl/KCl). All treated animals consumed comparable amounts of water and calories, and BHB treatment had no effect on body weight or blood glucose levels. After 5 weeks of treatment with BHB or BHB citrate, the kidneys of PKD animals were nearly indistinguishable from kidneys of wild-type animals both at the gross and histological level. BHB or BHB-citrate treated PKD rats showed striking reductions in the 2-kidney to body weight ratio (
FIG. 8A ) and the cystic area (FIG. 8B ) compared to water- and salt-treated controls. Neither wild-type kidneys nor other organs were affected by BHB treatment, indicating that the effect is specific to polycystic kidneys. - The results demonstrate dose-dependent benefits of BHB, and similar dose-dependent therapeutic effects from citrate, particularly at the 120 mM dosage. These results also demonstrate that the combination of BHB with citrate provides a synergistic response in PKD rats, even achieved at lower dosages of both BHB and citrate.
- GPR109A Activation in PKD. The results described above led to the unexpected conclusion that BHB has a strikingly strong dominant inhibitory effect on PKD progression. The most immediate and likely assumption would be that BHB may act by virtue of its property as a metabolite that is taken up by cells and used for energy generation. However, further experimentation led to unexpected results suggesting that this model is incorrect. Instead, the results surprisingly suggest that the beneficial action of BHB as an inhibitor of PKD progression is due to the activation of a specific receptor termed GPR109A. GPR109A is a member of the class of G-protein coupled receptors. It has recently been identified as the niacin receptor and it mediates the lipid-lowering effects of niacin due to its activation on adipocytes. It has been found that GPR109A is not only activated by niacin but also by high concentrations of BHB such as may occur during fasting-induced ketosis. The inventors of the present disclosure speculated that GPR109A may be expressed on cells in the kidney and that treatment with BHB would lead to its activation and affect PKD progression. To test this, GPR109A knockout mice were crossed with a PKD model. In these mice, the loss of GPR109A surprisingly indeed led to accelerated PKD progression, indicating that GPR109A is normally a suppressor if cyst growth. This is a novel finding that would have been unanticipated without the discoveries presented herein regarding the beneficial effect of BHB in ameliorating PKD progression. Additionally, treatment with niacin, a GPR109A agonist, ameliorates PKD progression in PKD mice expressing GPR109A but not in GPR109A knockout mice. For example, as presented in
FIG. 9 , PKD progression (as assessed by 2-kidney weight to total body weight ratio, 2KW/TBW) was ameliorated by niacin treated PKD mice (10 mg/kg, daily ip, from postnatal day 8-21) that express GPR109A (Genotype 1), while niacin treatment had no beneficial effect on PKD progression in the GPR109A knockout mice (Genotype 2). - All patents, patent applications, and publications cited in this specification are herein incorporated by reference to the same extent as if each independent patent application, or publication was specifically and individually indicated to be incorporated by reference. The disclosed embodiments are presented for purposes of illustration and not limitation. While the invention has been described with reference to the described embodiments thereof, it will be appreciated by those of skill in the art that modifications can be made to the structure and elements of the invention without departing from the spirit and scope of the invention as a whole.
Claims (23)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/240,605 US20210244695A1 (en) | 2019-03-14 | 2021-04-26 | Methods and Compositions for Supporting Renal Health |
US18/365,856 US20240000735A1 (en) | 2019-03-14 | 2023-08-04 | Compositions and Methods for Dietary Management |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962818538P | 2019-03-14 | 2019-03-14 | |
US16/819,079 US11013705B2 (en) | 2019-03-14 | 2020-03-14 | Methods and compositions for supporting renal health |
US17/240,605 US20210244695A1 (en) | 2019-03-14 | 2021-04-26 | Methods and Compositions for Supporting Renal Health |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/819,079 Continuation US11013705B2 (en) | 2019-03-14 | 2020-03-14 | Methods and compositions for supporting renal health |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/015796 Continuation-In-Part WO2022173813A1 (en) | 2019-03-14 | 2022-02-09 | Improved bhb-citrate formulations for promoting health |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210244695A1 true US20210244695A1 (en) | 2021-08-12 |
Family
ID=72423085
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/819,079 Active US11013705B2 (en) | 2019-03-14 | 2020-03-14 | Methods and compositions for supporting renal health |
US17/240,410 Abandoned US20210244694A1 (en) | 2019-03-14 | 2021-04-26 | BHB-Citrate Combination Products for Renal Health and Treating Disease |
US17/240,605 Abandoned US20210244695A1 (en) | 2019-03-14 | 2021-04-26 | Methods and Compositions for Supporting Renal Health |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/819,079 Active US11013705B2 (en) | 2019-03-14 | 2020-03-14 | Methods and compositions for supporting renal health |
US17/240,410 Abandoned US20210244694A1 (en) | 2019-03-14 | 2021-04-26 | BHB-Citrate Combination Products for Renal Health and Treating Disease |
Country Status (7)
Country | Link |
---|---|
US (3) | US11013705B2 (en) |
EP (1) | EP3937920A4 (en) |
CN (1) | CN114144174A (en) |
AU (1) | AU2020235643A1 (en) |
CA (1) | CA3129569A1 (en) |
MX (2) | MX2021011222A (en) |
WO (1) | WO2020186154A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
WO2022173813A1 (en) * | 2021-02-09 | 2022-08-18 | The Regents Of The University Of California | Improved bhb-citrate formulations for promoting health |
US20210252045A1 (en) * | 2019-12-11 | 2021-08-19 | John I. Toohey | Method for inactivating and removing disease-related levels of sulfane sulfur from affected biological tissues with special relevance to Covid-19 virus infection |
US20230119628A1 (en) * | 2020-03-27 | 2023-04-20 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid -19 and related viral infections |
RU2763933C1 (en) * | 2020-12-24 | 2022-01-11 | Юлия Викторовна Мукий | Test system for identifying a mutation in the btpkd gene of the domestic dog (canis lupus familiaris), causing polycystic kidney disease |
EP4366720A1 (en) * | 2021-07-09 | 2024-05-15 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
US20240065991A1 (en) * | 2022-08-26 | 2024-02-29 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777170A (en) * | 1987-02-03 | 1988-10-11 | Heinrich William A | Method to prevent and treat the signs and symptoms of motion sickness |
WO1995009144A1 (en) | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | Nutritive water soluble glycerol esters of hydroxy butyric acid |
EP1146075A1 (en) * | 2000-04-10 | 2001-10-17 | Alusuisse Martinswerk GmbH | Process for manufacture of fillers having improved bulk density stability and flowability |
JP5114631B2 (en) * | 2003-09-01 | 2013-01-09 | 有限会社アーザス | β-Hydroxy short to medium chain fatty acid polymer |
US20060083727A1 (en) * | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
US20090247589A1 (en) * | 2006-09-14 | 2009-10-01 | The Brigham And Women's Hospital, Inc. | Monocarboxylates for modifying macrophage function |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
US9744152B2 (en) * | 2010-07-19 | 2017-08-29 | Ic-Medtech Corporation | Vitamins C and K for treating polycystic diseases |
MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
US10285961B2 (en) * | 2014-02-06 | 2019-05-14 | University Of Houston System | Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof |
CN104464625B (en) | 2014-12-10 | 2016-09-21 | 合肥鑫晟光电科技有限公司 | Image element circuit and driving method, array base palte, display device |
AR102869A1 (en) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | QUICK ACTION INSULIN COMPOSITIONS |
US9364456B1 (en) | 2015-06-30 | 2016-06-14 | University Of South Florida | Ketone esters for treatment of angelman syndrome |
US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
WO2018187852A1 (en) * | 2017-04-12 | 2018-10-18 | Cavaleri Franco | Butyrate and beta-hydroxybutyrate compositions and methods of use thereof |
EP3398600A1 (en) | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Modified release nicotinamide |
EP3654963A4 (en) * | 2017-07-21 | 2021-04-14 | Buck Institute for Research on Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
CN107536035A (en) * | 2017-08-14 | 2018-01-05 | 迈德同信(武汉)科技股份有限公司 | A kind of functional food containing ketone and application thereof |
BR112020004053A2 (en) | 2017-08-31 | 2020-09-01 | Lonza Llc | health promotion composition and methods of using supplements |
US20190262415A1 (en) * | 2018-02-26 | 2019-08-29 | Ketologie LLC | Supplement for inducing and sustaining nutritional ketosis |
-
2020
- 2020-03-13 WO PCT/US2020/022619 patent/WO2020186154A1/en active Application Filing
- 2020-03-13 MX MX2021011222A patent/MX2021011222A/en unknown
- 2020-03-13 CN CN202080035880.XA patent/CN114144174A/en active Pending
- 2020-03-13 CA CA3129569A patent/CA3129569A1/en active Pending
- 2020-03-13 EP EP20769024.9A patent/EP3937920A4/en active Pending
- 2020-03-13 AU AU2020235643A patent/AU2020235643A1/en active Pending
- 2020-03-14 US US16/819,079 patent/US11013705B2/en active Active
-
2021
- 2021-04-26 US US17/240,410 patent/US20210244694A1/en not_active Abandoned
- 2021-04-26 US US17/240,605 patent/US20210244695A1/en not_active Abandoned
- 2021-09-14 MX MX2022012079A patent/MX2022012079A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022012079A (en) | 2022-10-18 |
US11013705B2 (en) | 2021-05-25 |
AU2020235643A1 (en) | 2021-09-30 |
EP3937920A1 (en) | 2022-01-19 |
WO2020186154A1 (en) | 2020-09-17 |
CA3129569A1 (en) | 2020-09-17 |
CN114144174A (en) | 2022-03-04 |
US20210244694A1 (en) | 2021-08-12 |
US20200289444A1 (en) | 2020-09-17 |
MX2021011222A (en) | 2022-09-28 |
EP3937920A4 (en) | 2022-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11013705B2 (en) | Methods and compositions for supporting renal health | |
CA2784836C (en) | Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb) | |
EP2704734B1 (en) | Composition useful for the treatment of lipid metabolism disorders | |
CN112351774A (en) | Compositions and methods for ketone stacking of beta-hydroxybutyrate and acetoacetate | |
WO2007049818A1 (en) | Anti-fatty liver, anti-obesity or hypolipidemic composition | |
WO2010106798A1 (en) | Agent for promoting energy consumption | |
KR20090074221A (en) | Nutrient sensor | |
JP6218870B2 (en) | Composition for preventing or treating nonalcoholic liver disease or insulin resistance comprising ginsenoside F2 | |
KR102239075B1 (en) | Composition for Preventing or Treating Sarcopenia Comprising IF1 | |
KR20200027976A (en) | Propionic acid and / or butyric acid for use in the prevention and / or supportive therapeutic treatment of Parkinson's disease | |
JP2008143811A (en) | Lipid metabolism promoting composition | |
CN112220790A (en) | Application of tetrahydropyrimidine and derivatives thereof in preventing and/or treating intestinal diseases | |
US20230285348A1 (en) | Compositions and methods for weight loss maintenance | |
US20240000735A1 (en) | Compositions and Methods for Dietary Management | |
JP2010222284A (en) | Blood gip increase inhibitor | |
EP3560340A1 (en) | Composition for promoting vegetable lipids excretion and comprising allulose | |
WO2015118699A1 (en) | Satiety maintaining agent and method for maintaining feeling of satisfaction | |
US20220023393A1 (en) | Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing if1 as active ingredient | |
ES2286899T3 (en) | METHOD FOR PREPARING A METABOLIC REGULATOR OF GLUCOLITICS. | |
KR20070044198A (en) | Anti-metabolic syndrome treatment with fumaric acid and fumaric acid derivatives | |
WO2009093353A1 (en) | Medicinal composition | |
US11452704B2 (en) | Prevention and treatment of muscle wasting with ketone supplementation | |
US10285967B2 (en) | Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories | |
JP2010111585A (en) | Feed having functionality, food and pharmaceutical composition | |
WO2020066158A1 (en) | Fat accumulation inhibitor and blood lipid level improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA SANTA BARBARA;REEL/FRAME:065565/0797 Effective date: 20210712 |